Review Article

Oxidative Stress in Parkinson’s Disease: Potential Benefits of Antioxidant Supplementation

Sandro Percário, Aline da Silva Barbosa, Everton Luiz Pompeu Varela, Antônio Rafael Quadros Gomes, Michelli Erica Souza Ferreira, Thayana de Nazaré Araújo Moreira, and Maria Fani Dolabela

1Oxidative Stress Research Laboratory, Institute of Biological Sciences, Federal University of Pará, Av. Augusto Corrêa, 01, Belém, Pará, Brazil 66075-110
2Institute of Health Sciences, Federal University of Pará, Av. Augusto Corrêa, 01, Belém, Pará, Brazil 66075-110

Correspondence should be addressed to Sandro Percário; spercario49@gmail.com

Received 2 April 2020; Revised 6 September 2020; Accepted 21 September 2020; Published 12 October 2020

Academic Editor: Patricia Morales

Copyright © 2020 Sandro Percário et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Parkinson’s disease (PD) occurs in approximately 1% of the population over 65 years of age and has become increasingly more common with advances in age. The number of individuals older than 60 years has been increasing in modern societies, as well as life expectancy in developing countries; therefore, PD may pose an impact on the economic, social, and health structures of these countries. Oxidative stress is highlighted as an important factor in the genesis of PD, involving several enzymes and signaling molecules in the underlying mechanisms of the disease. This review presents updated data on the involvement of oxidative stress in the disease, as well as the use of antioxidant supplements in its therapy.

1. Introduction

Parkinson’s disease (PD) is considered cosmopolitan and makes no distinction between social classes or between races, affecting both men and women, especially in the age range between 55 and 65 years, but it tends to occur with greater frequency in men [1, 2].

It is estimated that this disorder affects approximately 1% of the world population older than 65 years, representing up to 2/3 of all patients with movement disorders throughout the world [3]. PD has become increasingly more common with advances in age, reaching proportions of 2.6% of the population over 85 years old.

According to Silberman et al. [4], the number of individuals older than 60 years has been increasing, as has life expectancy in developing countries. Thus, along with health issues associated with an aging population, PD also imposes a significant impact on the economic, social, and health structures of these countries [5]. Therefore, a greater knowledge about the disease and an improvement of the planning of public health to minimize its impact in the future are necessary. Moreover, it is estimated that by 2020, approximately 40 million people worldwide will develop motor disorders secondary to PD [2, 6].

2. The Involvement of Oxidative Stress in PD

Oxidative stress is the result of many metabolic processes essential to the body. On the other hand, it can exert a toxic and deleterious role in the body [7–8].

Oxidative changes are highlighted as an important factor in the genesis of Parkinson’s disease (Figure 1), with the activation of glial cells being the main source of oxidative stress [9]. Some key enzymes are involved in the genesis of oxidative species derived from oxygen and nitrogen, namely, reduced nicotinamide adenine dinucleotide phosphate oxidase (NADPH), inducible nitric oxide synthase (iNOS), and
astrocytic myeloperoxidase (MPO) [10–16], as well as inflammatory factors, such as tumor necrosis factor alpha (TNF-α) [17] and cyclooxygenase-2 (COX-2) [9]. During the pathogenesis of PD, the production of oxygen-reactive species damages the substantia nigra through lipid peroxidation, protein oxidation, and DNA oxidation. This phenomenon seems to be induced mainly by changes in iron content of the brain, mitochondrial dysfunction, monoamine oxidase (MAO) activation, or even by changes in the antioxidant defense system [18–23].

Additional redox pathways involved in PD are androgen receptor-induced neurodegeneration [24], production of oxidatively modified forms of α-synuclein and increased α-synuclein aggregation [25, 26], degradation of antioxidant enzyme quinone oxidoreductase 1 (NQO1) [27], reduction of the deglucose activity of protein DJ-1 [28], activation of gene LRRK2 [29], and tetrahydrobiopterin (BH4) and tyrosine hydroxylase (TH) metabolism impairment [30].

Other evidence of oxidative stress involvement in PD was given by Colamartino et al. [31], who demonstrated that L-dihydroxyphenylalanine (L-DOPA) therapy decreases markers of lipid and protein peroxidation and increases total levels of reduced glutathione (GSH). In addition, L-DOPA and carbidopa can reduce damage to DNA and micronuclei induced by hydrogen peroxide (H₂O₂) in vitro.

Indeed, increased levels of oxidative stress markers are already found in blood from PD patients [32–34] and animal models of the disease [35]. In this sense, Farias et al. [36], investigating the peripheral biomarkers of reactive oxygen species (ROS) and reactive nitrogen species (RNS) in PD patients, found increased lipid hydroperoxides (LOOH), malondialdehyde (MDA) levels, and superoxide dismutase (SOD) activity, alongside decreased catalase (CAT) activity. Furthermore, these authors suggest that MDA may be a PD biomarker, while LOOH and SOD would be associated with late PD features.

To study oxidative changes in this neurodegenerative disease, an experimental mouse model of the disease is often used, in which damage to the dopaminergic neurons of the substantia nigra pars compacta is induced by the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which promotes activation of microglial cells [9]. The peripheral administration of this neurotoxin promotes important gliosis, accompanied by increased activation of iNOS in the substantia nigra, as well as of NADPH oxidase and MPO.

Furthermore, protein oxidation has already been identified as a marker of oxidative damage in postmortem brain tissue from PD patients [37].

Abraham et al. [38] evaluated the possibility of oxidative damage to red blood cells of PD patients by evaluating the activity of antioxidant enzymes, verifying that the activities of SOD, CAT, glutathione peroxidase (GSH-Px), and glucose-6-phosphate dehydrogenase (G6PD) were significantly lower in PD patients. Consequently, these authors suggested the involvement of oxidative stress as a risk factor for the disease and pointed out its importance in the underlying mechanisms of neurodegeneration in PD.

Venkateshappa et al. [39] evaluated the redox state of the substantia nigra and caudate nucleus during physiological aging in the human brain by assessing the expression of glial fibrillary acidic protein (GFAP) and activity of mitochondrial complex 1. The authors observed a significant increase in protein oxidation, loss of mitochondrial complex 1 activity, and increase in astrocytic proliferation in the substantia nigra compared to the caudate nucleus as age increased. These changes in the substantia nigra were attributed to a significant decrease in the antioxidant function represented by SOD, GSH-Px, and GSH, and a decreasing trend of GSH and CAT with age. However, these parameters showed no significant differences in the caudate nucleus. These results led the authors to suggest that the substantia nigra suffers extensive oxidative damage, loss of antioxidants and mitochondrial function, and increased expression of GFAP during physiological aging, changes that could make it more vulnerable to neurotoxic environments, thereby contributing to selective degeneration during the evolution of PD.

**Figure 1:** Sources of oxidative stress in Parkinson’s disease.
The oxidative imbalance involved in PD neurodegenerative processes seems to be a multifactorial phenomenon triggered by factors such as the aging of the brain, genetic predisposition, mitochondrial dysfunction, production of free radicals, and environmental toxins [15, 35, 40–41]. Nevertheless, some mechanisms are of key importance for the development of PD (Figure 2).

2.1. Iron and Iron-Dependent Free Radical Production. Iron also plays an important role in the oxidative changes of Parkinson’s disease, as it is present in various regions of the brain, noteworthy in dopaminergic neurons of the substantia nigra [42–44]. Iron accumulation associated with neuromelanine can represent one of the causes of increased free radicals in the substantia nigra and consequently lead to oxidative stress and neurodegeneration [42, 45].

Being rich in this metal, dopaminergic neurons are very susceptible to Fenton’s or Haber-Weiss’ reactions, which convert H₂O₂ to hydroxyl radicals, powerful oxidizing agents. Therefore, the presence of large quantities of ferrous ions (Fe²⁺) in the substantia nigra promotes high oxidative stress, DNA damage, and cell death by autophagy [46]. Additionally, under the action of SOD, free radical superoxide (O₂⁻) undergoes dismutation to H₂O₂, which, in the presence of high concentrations of iron, produces hydroxyl radicals (OH⁻) through Fenton’s reaction.

In this context, Hochstrasser et al. [47] and Olivieri et al. [48] studied the role of ceruloplasmin in this disease, an extracellular ferroxidase that oxidizes iron from its toxic ferrous form to the nontoxic ferric form. Analyzing the cerebrospinal fluid of patients with PD, Olivieri et al. found higher levels of ceruloplasmin oxidation in these patients than in controls or in subjects with other neurodegenerative diseases. Similarly, ceruloplasmin-deficient mice showed accumulation of iron in the central nervous system and increased lipid peroxidation [49], and ceruloplasmin deficiency due to copper dyshomeostasis is reported in PD patients [50]. Treatment with another iron chelator, lactoferrin, also offered protection against oxidative stress in MPTP-induced PD mice [51].

Moreover, iron can lead to the formation of Lewy bodies through the aggregation of α-synuclein [52–57]. Alpha-synuclein is an abundant protein in presynaptic terminals and is responsible for the formation of Lewy bodies—mainly by its iron-dependent binding to cytochrome c and mitochondrial damage—via regulation of mitochondrial complex 1, increasing susceptibility of the substantia nigra to free radicals in PD [58–63]. Bayir et al. [61] and Rostovtseva et al. [64] investigated the biochemical mechanism of action of α-synuclein and showed that this protein can bind to anionic lipids (such as cardiolipin), exerting peroxidase function while protecting nigral neurons against damage by H₂O₂ and consequently preventing apoptosis. Shahnawaz et al. [65] suggest that detection of α-synuclein by protein misfolding cyclic amplification in cerebrospinal fluid may provide an efficient biochemical test for the diagnosis of PD.

Reinforcing the importance of iron in the underlying neuropathogenic changes of PD, the use of iron chelators in models of nigral neurodegeneration induced by proteasome inhibitors showed a decreased loss of dopaminergic neurons as well as a decreased α-synuclein aggregation and a consequential reduced formation of Lewy bodies [54, 66].

In addition, the toxic effects of oxidative stress seem to be boosted by environment-present substances, such as herbicide

**Figure 2:** Mechanisms of free radical involvement in Parkinson’s disease.
parquat (1,1′-dimethyl-4,4′-bipiridina dichloride), frequently used in agriculture, which operates in synergism with iron when absorbed by the organism. As a consequence of parquat poisoning, the increase in free radical production in several areas of the body, including the substantia nigra, promotes the synthesis of glutathione and inhibits the toxicity of α-synuclein [28, 90].

Steckley et al. [91], Qi et al. [92], and Feng et al. [93] attributed the regulation of oxidative stress and, consequently, neuronal apoptosis to the gene PUMA, one of the genes of the Bcl-2 family. This gene is responsible for the permeability of the mitochondrial membrane. Activation of the LRRK2 gene may also be responsible for increased oxidative stress and neuronal loss in PD [29].

As suggested by Chen et al. [94] and Haskew-Layton et al. [95], the negative regulation of genes related to antioxidant defenses via stimulation of nuclear factor erythroid 2 (NF-E2) is positively correlated with the destruction of astrocytes. The same happens with PTEN-induced putative kinase 1 (PINK1), a gene that inhibits mitochondrial dysfunction and is positively related to neuroprotection [96].

According to Cook et al. [97], mutations in the parkin gene and the abnormal accumulation of α-synuclein proteins in certain dopaminergic neurons are closely related to PD and oxidative stress. In this sense, Basso et al. [98], by inhibiting transglutaminase, observed a reduction in markers of oxidative stress and a decrease in neuronal death, features of PD.

2.4. Role of Nitric Oxide (NO). Some studies suggest that NO plays an important role as a mediator of the neurotoxicity associated with mitochondrial damage in several neurological disorders, such as PD [99]. Under pathological conditions, the expression of iNOS and NADPH oxidase activity occurs in microglia, leading to high production of NO and O2•−. These two free radicals react to produce peroxynitrite radicals (ONOO−), a highly reactive molecule that can cause damage to dopaminergic neurons.

Evidencing the importance of NO synthesis and its byproducts in the physiopathology of PD, nitration of tyrosine residues is a known marker of oxidative stress in patients with Parkinson disease and is induced by ONOO− [100–101]. In this context, Sue et al. [102] studied the effects of ethyl pyruvate (EP), a known scavenger of reactive oxygen species, in mice treated with MPTP, demonstrating that EP mitigates iNOS expression in the substantia nigra, reducing oxidative damage.

Similarly, Yeung et al. [103] demonstrated that aldose reductase deficiency, a tyrosine hydroxylase cofactor involved in dopamine synthesis, can induce oxidative stress by increasing NO and nitrite (NOx), causing the loss of dopaminergic neurons and autophagic abnormalities in animals with PD.

Notwithstanding, iNOS knockout mice are more resistant to the neurodegenerative effects of MPTP than wild-type mice [10]. The same effect is observed in animals treated with specific inhibitors of neuronal nitric oxide synthase (nNOS), such as 7-nitroindazole [14].

Conversely, Rathnayake et al. [17] identified that low serum NO metabolites (nitrites and nitrates (NOx)) are associated with cognitive impairment in PD patients, proposing NOx as a marker of early-stage PD.

Indeed, the dopaminergic neurotoxin MPTP is associated with the induction of iNOS in the substantia nigra, leading to the formation of ONOO− [52, 104], and the administration of MPTP in rats induces considerable gliosis in the substantia nigra, as well as a significant positive regulation over iNOS.
[105]. Moreover, in iNOS gene-deficient rats, the neurodegenerative effects of MPTP administration were less prominent, suggesting the inhibition of iNOS as a potential target for drugs in the treatment of PD [105]. Additionally, the use of nitric oxide synthase (NOS) inhibitors prevents dyskinesia in Parkinson’s disease, at least in part via inhibition of glial cell activation and iNOS expression, showing the role of NO in the pathogenesis of PD [106]. Moreover, astrocytes express high levels of MPO, which produce hypochlorous acid (HOCl) from the reaction of $\text{H}_2\text{O}_2$ and chloride ions (Cl$^-$), causing additional oxidative damage. The presence of HOCl can increase the amount of OH$^-$, as HOCl can also react with O$_2^•$. Myeloperoxidase also catalyzes the conversion of nitrite from its nonreactive form (NO$_2^-$) to its free radical form (NO$_2^•$), enhancing protein damage [9].

This was also evidenced in the experimental model of neurodegeneration proposed by Ebadi and Sharma [107], in which the activation of iNOS, the synthesis of NO, and the production of peroxynitrite were associated with nigrostriatal dopaminergic neurodegeneration and that animals that overexpressed the genes metallothioneins 1 and 2 showed greater protection against damage caused by oxidative stress due to iNOS activation.

2.5. Role of MAO, MPO, and NADPH Oxidase. In addition to the free radical-generating processes already mentioned, the reactions catalyzed by MAO are also potential free radical generators and are related to the decrease in intrinsic antioxidant defenses [108–109].

At the intracellular level, dopamine is degraded both by MAO and by autoxidation [110–111]. The metabolism of dopamine leads to the formation of dihydroxyphenylacetic acid (DOPAC) and $\text{H}_2\text{O}_2$ [112]. The autooxidation of intracellular dopamine produces $\text{H}_2\text{O}_2$ and dopamine-quinone, which participate in nucelophilic reactions associated with sulphydryl groups, leading to further reduction of GSH-Px activity [113].

Dopamine-quinone is also capable of inhibiting the function of the dopamine transporter within synaptosomes by inhibiting the enzyme tyrosine hydroxylase, resulting in incomplete ATP synthesis [114–116]. The ratio between GSH and oxidized glutathione (GSSG) is decreased during synaptosome degeneration, thus propitiating the formation of even more free radicals [117–118]. Furthermore, the decrease in the GSH/GSSG ratio can impair free radical scavenging by GSH, as a reflection of constant oxidation of the GSH molecule and consequent depletion of cellular GSH [119]. In studies with cells in culture, GSH depletion has been related to the toxicity of dopamine and $\text{H}_2\text{O}_2$ [120].

In addition to dopamine metabolism, MAO can metabolize MPTP by the action of MAO-B. MPTP is oxidized to dihydroxyprydine (MPDP$^+$) and converted to N-methyl-4-phenylpyridine (MPP$^+$) by autoxidation, binding to dopaminergic transporter proteins. Subsequently, it is retaken by dopaminergic nigral neurons [121]. Once in the cytosol, MPP$^+$ promotes the inhibition of complex 1, as well as the production of free radicals (through the activation of NADPH oxidase, microglial iNOS, and astroglial myeloperoxidase) and the production of proinflammatory cytokines, such as TNF-$\alpha$ and interleukin-1$\beta$ (IL-1$\beta$). These phenomena contribute to the death of dopaminergic neurons in experimental models of PD [12–13, 122].

Likewise, MPO is an important component of the PD puzzle. In postmortem mesencephalic analysis of PD patients, Choi et al. [13] observed significantly higher levels of MPO than in controls. In the same study, using the MPTP model of PD, they found high levels of 3-chlorotyrosine, a marker of MPO protein damage. These authors also demonstrated that MPO-deficient mice are resistant to MPTP neurotoxicity. In parallel, Maki et al. [16] also demonstrated that MPO plays an important role in oxidative damage to $\alpha$-synuclein. Moreover, the prooxidant effect of MPTP in animal models of PD was minimized using paroxetine (an antidepressant drug), which promoted the reduction of astroglial MPO expression, production of ROS through NADPH oxidase, and the expression of proinflammatory cytokines, decreasing the loss of dopaminergic neurons and improving motor functions. These effects suggest the role of oxidative stress in the pathogenesis of PD, and therefore, the use of drugs designed to decrease the neurodegenerative effects caused by free radicals displays great potential for the treatment of the disease [123].

Furthermore, the role of NADPH oxidase in oxidative damage in PD was demonstrated through the treatment of PD-induced mice with a nonselective agonist of cannabinoid receptor. This treatment promoted suppression of O$_2^•$ production by NADPH oxidase in the microglia, and oxidative damage to nucleic acid and protein levels were reduced [124]. The damage to nucleic acid was evaluated by the dosage of 8-hydroxy-2-deoxyguanosine (8-OHdG), a marker of oxidative damage to the DNA. Likewise, 8-OHdG was elevated in the cerebrospinal fluid of patients with PD in comparison to control subjects [32].

3. Antioxidant Approaches to PD

Considering all factors related to oxidative stress overstimulation in the underlying mechanisms of PD, numerous studies have suggested the potential beneficial effects of antioxidant supplementation in PD treatment, and several approaches have been attempted so far, from traditional antioxidant schemes, such as vitamin E, C, and $\beta$-carotene supplementation, to more innovative and bold approaches, such as the use of nanoparticles to deliver antioxidant molecules, among several others.

Indeed, several studies show that brains from PD patients present low levels of endogenous antioxidants, such as glutathione and coenzyme Q$_{10}$ (CoQ$_{10}$) [125], increased oxidation of dopamine [115], and high levels of iron [126], suggesting that oxidative stress plays a crucial role in the pathology of PD. Considering the greater iron content of some areas of the brain [127], low levels of GSH are expected [128], as well as increased lipid peroxidation [129] and oxidation of nucleic acids [130].

In addition, Campolo et al. [131] suggest that the reduction of the total antioxidant capacity observed in the PD prodromal, and when associated with olfactory loss and
cardiovascular dysautonomia, may represent a useful biomarker for an early and integrative PD diagnosis.

In this sense, antioxidants can provide a significant advance in the therapeutic treatment of PD, as it is believed that Parkinson’s neurodegeneration is linked to dietary habits and that nutritional deficiency of antioxidant compounds, such as folic acid [132], vitamins (A, C, E, and niacin), and selenium, increases the risk of subjects developing PD [133–134]. Thus, the therapeutic approach for the treatment of PD must include the modulation of oxidative stress using antioxidants, which, at least partially, may be provided by an adequate diet.

Several antioxidant molecules have been used both in experimental and clinical studies of PD and will be categorized and presented henceforth by its source or chemical class when appropriate.

3.1. Endogenous Molecules

3.1.1. Melatonin. A natural antioxidant capable of reducing cellular oxidative stress, melatonin protects mitochondrial functions in vitro. Low levels of melatonin were found in PD patients [135]. Zampol and Barros [136] prompted a study indicating that melatonin administration to cultured cells reversed α-synuclein damage to mitochondria. Additionally, Patki and Lau [137] investigated whether melatonin could reverse neurobehavioral deficits and mitochondrial disorders in an experimental model of PD, suggesting that, in the long term, melatonin protects not only mitochondria but also neurons in an animal model of chronic PD. Due to this factor, melatonin can potentially be effective in slowing the progression of idiopathic Parkinson’s disease and reducing oxidative stress and respiratory chain inhibition in other mitochondrial diseases. In a similar study, Paul et al. [138] identified that the administration of melatonin protects against behavioral deficits and loss of nigral dopamine and reduces oxidative stress by eliminating OH− radicals and boosting the activity of antioxidant enzymes in an animal model of PD. Similar results were observed by Li et al. [139] and Rasheed et al. [140]. Curiously, despite promoting the reversion of several rotenone- [141] and 6-OHDA-induced damage in rats [142], melatonin supplementation to animals was unable to improve locomotor activity. In addition, administration of melatonin to humans promoted reduction of COX-2 activity, nitrites and nitrates, and lipid peroxides that correlated with clinical improvement of PD patients [143]. Nevertheless, the association of melatonin with L-DOPA significantly decreased the side effects of L-DOPA therapy in mice [144]. A particular aspect of melatonin administration in PD lies on its effect on the occurrence of sleep disorders, a common finding in PD patients. In this regard, melatonin treatment promoted sleep improvement in animal studies [145–146], while its effect on clinical trials is controversial [147–149]. Notwithstanding, one meta-analysis study suggests melatonin therapy as highly indicated for the treatment of sleep disorders in PD patients [150].

3.1.2. Coenzyme Q. Another important antioxidant system is represented by CoQ10, a mitochondrial electron carrier that also acts in the prevention of oxidative damage [151–152]. It also acts as a cofactor and activator of proteins of mitochondrial coupling [153]. However, the mechanisms by which CoQ10 protects dopaminergic neurons against degeneration are still not well understood, although it is known that the reduction of CoQ10 levels in PD patients induces changes in ATP synthesis and damage to the mitochondrial membrane [125]. In this sense, oral administration of CoQ10 in animal models and in patients with PD caused a continuous decrease in mitochondrial dysfunction [154–155], loss of dopamine and dopaminergic axons [156], protection of dopaminergic neurons against excitotoxin-induced neurodegeneration in PD [157–158], and partial improvement of motor performance [159]. However, a clinical trial conducted with 600 patients showed no evidence of benefit for CoQ10 supplementation [160], a result supported by a recent meta-analysis [161].

3.1.3. Urate. High levels of urate have been associated with a lower risk for PD [162], and changes in urate levels can predict the development of PD in animal models of the disease [163]. Coolen et al. [164], in a study with daily oral supplementation of 5000 mg of ATP in humans, identified that there was an increase in uric acid. In parallel, Andreadou et al. [165] detected the presence of reduced serum levels of this antioxidant molecule in patients with PD and suggested the potential use of this molecule in the therapy of the disease. Indeed, feeding a 1% uric acid diet to rats reversed PD symptoms [166], effects that may be related to NF-E2-related factor 2 (Nrf2) bound to the antioxidant response element (Nrf2-ARE) pathway [167]. Moreover, administration of inosine, a urate precursor, was safe and promoted improvement of PD symptoms in humans [168].

3.1.4. β-Nicotinamide Adenine Dinucleotide (NAD). NAD is known to decrease in PD [169]. To investigate whether NAD replenishment is beneficial in a 6-OHDA-induced mouse model of PD, Shan et al. [170] injected NAD in the striatum, resulting in less motor deficits and dopaminergic neuronal damage to the animals.

3.1.5. Kynurenic Acid (KA). KA and quinolinic acid (QA) are metabolites of tryptophan degradation and have important neurological activities. KA/QA ratio changes are associated with neurological disorders, such as PD. KA administration prevented QA-induced brain damage in an ex vivo rat model of PD, preventing changes in Nrf2 levels, oxidative damage, and mitochondrial dysfunction [171].

3.1.6. L-Carnitine. Reactive gliosis and neuroinflammation are features of PD and might result from fatty acid oxidation. In this sense, L-carnitine inhibited lipopolysaccharide-induced oxidative stress in microglial cells, reversing the effects of detrimental neuroinflammation in vitro [172].

3.1.7. Glutamine. Glutamine has a positive role in reducing oxidative stress damage and suppressing MPTP-induced cytotoxicity in cultured PC12 cells. Moreover, glutamine restores SOD, GSH-Px, and lipid peroxidation markers to
basal levels in those cells, probably through inhibition of the PI3K/Akt signaling pathway [173].

3.1.8. *n*-3 Polyunsaturated Fatty Acids. Omega-3-polyunsaturated fatty acids (*n*-3 PUFA) have been widely associated with beneficial effects over different neurodegenerative diseases, such as PD. Hernando et al. [174] tested the effects of docosahexanoic acid (DHA) and its hydroxylated derivative, DHAAH, in a 6-OHDA-induced animal model of PD, showing a positive effect on Nrf2 pathway regulation in the treated group due to the potential antioxidant effect of these compounds.

3.1.9. Sulfur-Containing Antioxidants. Among the endogenous antioxidant molecules, some can easily promote a reducing environment within the cytoplasm, due to the particular aspects of the interaction between the intracellular environment and sulfur-hydrogen bonds that are present in these molecules. This provide these molecules with special antioxidant properties; thus, they are discussed as a separate group, alongside with N-acetyl cysteine, an exogenous molecule, yet an important precursor of endogenous GSH synthesis.

(1) *Lipoic Acid* (LA). Lipoic acid is another potent antioxidant that promotes the removal of free radicals and increases antioxidant defenses, boosting the levels of GSH, α-tocopherol, and ascorbic acid. LA can promote the reduction and prevention of oxidative stress, either in its oxidized form (LA) or in its reduced form, dihydrolipoic acid (DHLA). Due to this ability to prevent neuronal damage caused by ROS in the nervous system, LA supplementation has been suggested for the therapy of neurodegenerative diseases, including PD [175–177]. Bilska et al. [178] demonstrated that LA administration enhances the antioxidant defense system, slows the progression of neuronal degeneration, and improves the regeneration of injured tissues. This may be due to the increase in both GSH levels and activity of GSH-Px and glutathione-S-transferase (GST). Likewise, Zhou et al. [179] demonstrated that administration of alpha lipoamide, a neutral amide derivative of alpha-lipoic acid, restored the number of dopaminergic neurons in the midbrain and recovered mitochondrial function in an animal model of PD. Zhou and Cheng [180], in a 6-hydroxydopamine- (6-OHDA-) induced model of PD, demonstrated that LA alleviates 6-OHDA-induced cell injury, possibly by inhibiting autophagy mediated by the AMPK/mTOR pathway. These neuroprotective effects of lipoic acid were also observed for a combination of carnosine–alpha-lipoic acid in a model of early-stage PD [181]. Moreover, Zhang et al. [182] demonstrated that LA alleviates L-DOPA-induced dyskinesia in rats, and similar results were presented by Abdin and Sarhan [183], who found normalization of catalepsy score and apparent preservation of striatal integrity in rotenone-induced PD in rats.

(2) Reduced Glutathione. Among the endogenous antioxidant systems, the main antioxidant system seems to be the redox system of GSH, which protects cells against oxidative stress through three different pathways: direct scavenging of reactive oxygen species, transition metal chelation, and antioxidant cofactors (GSH is required for GSH-Px activity). The essential elements of these systems are GSH-Px, which reduces hydrogen peroxide or lipid peroxide, and GST, which combines electrons to GSH and some ATPase and, therefore, may reduce GSSG or GSH conjugates [184–185]. According to Yamamoto et al. [186], the inhibition of proteasomes induces GSH synthesis to protect nerve cells from oxidative damage. On the other hand, the decrease in glutathione levels results in oxidative stress and mitochondrial dysfunction, regarded as triggering factors in PD neurodegeneration [187]. It is also believed that a reduced GSH/GSSG ratio can increase ROS and RNS production [118] through the opening of GSH redox state-dependent transition pores of mitochondrial permeability [188]. Furthermore, high levels of ROS and RNS may also impair the operation of complex 1 by oxidation of significant residues within the complex and consequent reduction of glutathione reductase (GR) activity, an enzyme responsible for the reduction of GSSG [189–190]. Despite the inability of GSH to cross the blood–brain barrier [191], Sicchi et al. [192] administered GSH intravenously to untreated PD patients and found significant improvement for all subjects. Alternatively, glutathione analogs were also employed. Yamamoto et al. [193] tested YM737—a GSH analog—in a rat model of PD, with better results than GSH itself. Wassef et al. [194], who performed studies in transgenic *Drosophila melanogaster* flies overexpressing α-synuclein and methionine sulfoxide reductase (MSRA), observed that dietary supplementation with S-methyl-L-cysteine was able to prevent or alleviate the symptoms of PD since it participates in the antioxidant mechanism of MSRA, inducing an increase in enzyme activity. Another study demonstrated that supplementation with water containing the GSH precursor N-acetyl-L-cysteine (NAC) in mice that express human α-synuclein promotes a decrease in α-synuclein in the brain and protects, at least partially, the decrease in dopamine concentrations, characteristics that were associated with the reduction in nuclear factor kappa B (NF-κB) [195].

(3) Hydrogen Sulfide. Hydrogen sulfide is a gaseous neurotransmitter with neuroprotective effects. Sarukhani et al. [196] investigated its activity in an acute 6-OHDA animal model of PA and concluded that hydrogen sulfide produces a significant antiparkinsonism effect, protecting against 6-OHDA neurotoxicity, as it reduces malondialdehyde overproduction.

(4) N-Acetylcysteine. Known as an antioxidant and a GSH synthesis precursor for a long time, NAC was studied in two independent studies with similar results. Virel et al. [197], working with human mesenchymal cells, and Bonilla-Porras et al. [198], working with mice, demonstrated that 6-OHDA treatment caused GSH depletion that was not reversed by NAC cotreatment, despite the fact that this treatment improved antioxidant levels in both studies. According to the authors, this highlights the importance of GSH on brain metabolism. Moreover, Coles et al. [199] treated PD
3.2. Vitamins. The beneficial effects of antioxidant vitamins in PD were evaluated in a series of studies that assessed dietary vitamin intake using structured questionnaires. Indeed, Miyake et al. [200] evaluated the relation between the intake of antioxidant vitamins present in vegetables and fruit and the risk of patients developing PD in Japan, observing that a greater consumption of vitamin E and β-carotene is associated with a reduction in the risk of PD in this population. Moreover, Rijk et al. [201], studying 5342 individuals from the Rotterdam Study, suggested that high dietary intake of vitamin E may protect against the occurrence of PD. Similar results were found by Zhang et al. [202], Etminan et al. [203], and Schirinzi et al. [204]. Nevertheless, other authors failed to prove the beneficial effects of dietary antioxidant vitamin intake [133, 205–208], suggesting that the vitamin amount provided by the diet is insufficient [209]. Indeed, a recent cohort study conducted by Hughes et al. [210] investigated the intake of vitamins C and E and carotenoids on the risk of PD development and concluded that there are still no results that support the hypothesis that ingestion, alone or a combination of these antioxidant substances, decreases the risk of developing PD. Notwithstanding, in an experimental study, vitamin A and β-carotene dose-dependently destabilized preformed α-synuclein filaments [211], and the treatment of PD patients with α-tocopherol and ascorbic acid delays disease progression [212]. Moreover, research using 6-aminolevulinic acid in an experimental model of PD demonstrated the neuroprotective action of vitamin E through behavioral and histochemical evidence [213]. Zhu [132] suggests that in addition to vitamin C, other antioxidants are important in the diet for the reduction of the risk of PD, such as vitamins B6 and B12, S-adenosyl-L-methionine (SAME), and folic acid, based on the regulation of catechol-O-methyltransferase (COMT), an enzyme that acts in catecholamine degradation.

3.3. Phenols and Polyphenols

3.3.1. Tyrosol. A simple phenol present in extra virgin oil, tyrosol, was demonstrated to delay α-synuclein aggregation in a Caenorhabditis elegans model of PD. Additionally, tyrosol treatment reduced ROS levels and promoted the expression of specific chaperones and antioxidant enzymes [214].

3.3.2. Tricetin. Extracted from Ginkgo biloba, tricetin was demonstrated to confer neuroprotection against 6-OHDA-induced oxidative stress in a C. elegans model of PD. Moreover, it also induced the protein expression of Nrf2 and its transcriptional activation, resulting in the upregulated expression of heme oxygenase-1 [215].

3.3.3. Chrysin. Chrysin is a natural flavonoid found in bee propolis, honey, and several plants and was investigated in both the 6-OHDA [216] and the MPTP [217] models of PD, reversing neurochemical deficits, behavioral abnormalities, and oxidative stress in those animals.

3.3.4. Acteoside. Acteoside is a flavonoid reported to have antioxidant and neuroprotective effects. Li et al. [218] investigated its effect in a 6-OHDA zebrafish model of PD, demonstrating its ability to reduce neural damage and even prevent neural damage. In addition, pretreatment with acteoside could upregulate antioxidant enzymes by activating the Nrf2 signaling pathway.

3.3.5. Pinostrobin. Another flavonoid with antioxidant effects, pinostrobin was also used in the MPTP zebrafish model of PD with similar results as acteoside, as it significantly enhances Nrf2 expression and upregulates heme oxygenase-1 (HO-1) expression [219].

3.3.6. Curcumin. Like other flavonoids, curcumin is reported to have antioxidant and neuroprotective properties. Indeed, its use in both Drosophila melanogaster and 6-OHDA-induced PD in rat models resulted in improved locomotive abilities, less severe neurodegeneration, and decreased oxidative stress markers [220–221]. Similar results were found with demethoxycurcumin, a curcumin derivative [222].

3.3.7. Hesperidin. Hesperidin was reported to reduce the iron content in the heads of D. melanogaster and to restore dopamine levels and cholinergic activity, as well as to reduce Fe-induced mortality, oxidative stress, and mitochondrial dysfunction in this model of PD [223].

3.3.8. Naringenin. A citrus fruit flavanone, naringenin was employed in two independent studies using the MPTP-induced PD model in mice, leading to an overall reversal of PD-induced features, such as α-synuclein aggregation, as well as to lower oxidative stress levels and increased antioxidant parameters [224–225].

3.3.9. Resveratrol. Resveratrol is a very promising polyphenol, showing inhibition of α-synuclein aggregation in PD-induced mice [226], increased lifespan of MPTP-treated D. melanogaster [227], and protection for PC12 cells from rotenone oxidative damage, an effect partially mediated through the activation of the SIR/Akt1 signaling pathway [228]. In all three studies, oxidative stress was decreased in the resveratrol-treated groups, whereas antioxidant status was increased.

3.3.10. Genistein. Wu et al. [229] investigated the effects of genistein against the rotenone-induced PD model in human SH-SY5Y cells, which express a mutant form of α-synuclein. The authors demonstrated that genistein was able to prevent mitochondrial oxidative damage caused by rotenone to those cells. Further investigation led the authors to conclude that genistein can reduce oxidative stress damage and cell apoptosis, activating estrogen receptors and NF-E2L2 channels.

3.3.11. Rosmarinic Acid. Qu et al. [230] demonstrated that rosmarinic acid protected against iron-induced α-synuclein aggregation by upregulating HO-1 and inhibiting α-synuclein expression.
3.3.12. Salidroside. Wu et al. [231] administered salidroside to 6-OHDA-induced PD rats and demonstrated neuroprotection against oxidative stress, an effect probably related to the regulation of the Wnt/β-catenin signaling pathway.

3.3.13. Anacardic Acids. Anacardic acids are alkyl phenols mainly present in cashew nuts and were used to treat rotenone-induced PD in rats. Among several of the beneficial effects, the authors demonstrated that the use of anacardic acids prevented motor impairment and lipoperoxidation induced by rotenone, in part due to a modulatory action on mitochondria and SOD gene expression [232].

3.4. Terpenes

3.4.1. Thymol. Thymol is a dietary monoterpene and was tested to prevent neurotoxicity and neurodegeneration in rotenone-challenged rats. Rotenone-induced neurodegeneration is a well-established PD model with oxidative stress involvement that mimics the features of PD in humans. Thymol treatment significantly reduced dopaminergic neural loss and oxidative stress, resulting in clinical improvement to the animals and preservation of antioxidant defenses, as well as attenuation of inflammatory mediators [233].

3.4.2. Astragaloside IV. A triterpene extracted from the roots of Astragalus membranaceus, an herb known as Huang Qi that has been used for more than 5000 years in China, possesses anti-inflammatory and antioxidant properties in neurogenerative diseases and was employed to prevent damage caused by MPTP in rats and lipopolysaccharide-induced damage to BV2 microglial cells with promising results [234].

3.4.3. Carvacrol. It is a phenolic monoterpoid that is found primarily in the essential oil from oregano. Haddadi et al. [235] treated 6-OHDA-induced PD in rats with carvacrol, showing that a dose of 25 mg promoted significant memory deficit improvement in the animals.

3.4.4. β-Amirin. This pentacyclic triterpenoid compound is found in several medicinal plants and promotes excellent antioxidant activity, significantly reducing ROS in a C. elegans model of PD. Moreover, β-amirin treatment also exerted a protective effect on dopaminergic neurons, reducing cell damage and α-synuclein aggregation [236].

3.4.5. Asiatic Acid (AA). A triterpenoid used for the treatment of depression, asiatic acid is known for its antioxidant properties. AA was tested in three different PD models: PD transgenic Drosophila flies, where it caused significant improvement in climbing ability and prolonged the lifespan—effects attributed to AA antioxidant properties; rotenone-induced damage in SH-SYSY cells, where it protected mitochondria from oxidative stress and apoptosis; and in an isolated mitochondria model, where AA promoted membrane integrity and ATP production against the decline in membrane potential induced by α-synuclein. Considering that maintaining mitochondrial integrity is essential in PD, the authors suggested AA as an excellent candidate for PD prevention and therapy [237].

3.4.6. Geraniol. An acyclic monoterpene found in the essential oils of several aromatic plants, geraniol was used to prevent rotenone-induced mitochondrial damage in SK-N-SH cells, ameliorating intracellular redox status, preserving membrane potential, and reducing the expression of α-synuclein, features that corroborate enhanced cell viability [238].

3.5. Plant Extracts. Beyond using purified antioxidant molecules, several studies have considered the use of crude plant extracts to treat PD-like symptoms and the consequent morphological and biochemical modifications induced in PD models, mainly due to the synergistic effect of the antioxidant molecule content of such extracts. Some of these studies are summarized below.

3.5.1. Grape Skin. Moderate red wine consumption is considered to confer several health benefits, including protection against neurological diseases. These health benefits are suggested to come from resveratrol, a compound from grape skin that displays anti-PD effects [226–228]. Notwithstanding, Wu et al. [239] investigated the effects of grape skin extract (GSE) left from red wine production on a Drosophila model of PD, resulting in preservation of mitochondrial morphology and improvement of indirect flight muscle function, as well as in prolonged lifespan of the flies. Notably, the authors suggested that these effects of GSE are not accounted for by resveratrol alone.

3.5.2. Centella asiatica. It is a well-known medicinal plant native to southern Asia, Australia, and some Pacific Islands commonly used against circulatory dysfunction in Chinese traditional medicine. Teerapattarakan et al. [240] used a C. asiatica extract to treat rotenone-induced PD in rats and showed significant improvement in the travelled distance of treated rats, alongside a higher number of dopaminergic neurons in the substantia nigra and striatum, decreased MDA, and increased SOD and catalase expression.

3.5.3. Dendropanax morbifenus. This plant is an endemic species of South Korea that is extensively used in traditional medicine to treat several clinical complications. Park et al. [241] successfully used D. morbifenus leaf extracts to prevent behavioral deficits and dopaminergic neuron loss in the MPTP-induced PD mouse model. Chromatographic profiling of the extract identified chlorogenic acid as its major constituent, a well-known antioxidant agent.

3.5.4. Azadirachta indica. Similar to D. morbifenus, A. indica is a medicinal plant used for more than 2000 years in India and displays anti-PD properties. Curiously, it is called “arishta” in Sanskrit, which means “the eliminator of pain.” Indeed, treatment with A. indica extract to 6-OHDA-induced PD rats promoted improved motor behavior and reversed several biochemical modifications induced by 6-OHDA, such as the suppression of inflammatory factors, antioxidant enzymes, and iNOS expression [242].

3.5.5. Zizyphus spinachristi. Known as “Christ’s thorn jujube,” Zizyphus spinachristi is an evergreen tree native to northern and tropical Africa and Southern and Western
Asia. Fruits and leaves from the tree have been used in Ancient Egypt as food and medicine. Singh et al. [243] investigated the beneficial effects of Z. spinachristi fruit extract against MPTP-induced neurotoxicity in SH-SY5Y cells, demonstrating its ability to reverse cell damage and oxidative stress, effects accounting for its potent antioxidant properties.

3.5.6. *Apium graveolens*. *Apium graveolens* is used in Chinese traditional medicine and is routinely prescribed for the treatment of gout, diabetes, and hypertension. Chon-pathompinulkert et al. [244] tested the effect of the methanolic extract of the whole plant on the MPTP model of PD in rats and demonstrated significant improvement in behavioral performance and oxidative stress parameters, as well as an increased number of dopaminergic neurons.

3.5.7. *Ginkgo biloba*. Another potent antioxidant tested was the extract rich in flavonoids and terpenes obtained from leaves of *Ginkgo biloba*, which promoted effective protection to the neurons of animals exposed to MPTP in an experimental model of PD [245–246].

3.5.8. *Aspidosperma pyrifolium* Mart. *Aspidosperma* species are commonly used in folk medicine in Brazil, especially to treat malaria, and there are several ongoing studies in this regard. Among them, *A. pyrifolium* Mart. aqueous extract was tested against 6-OHDA-induced PD in rats, where the treated groups showed decreased PD features, including less lipid peroxidation and increased levels of dopamine, suggesting a potential for this extract in PD treatment [247].

3.5.9. *Olea europaea* L. Leaf extract from this ordinary olive tree has shown antioxidant and neuroprotective effects, which led Sarbishegi et al. [248] to investigate its effect against a rotenone-induced model of PD in rats, resulting in significant improvement of oxidative markers and blockage of depletion of tyrosine hydroxylase-positive neurons caused by rotenone exposure.

3.5.10. *Bacopa monnieri*. This plant is used in Ayurvedic medicine for the treatment of neurological disorders and displays high levels of antioxidant molecules. Tested against the MPTP-induced PD model in mice, the ethanolic extract of *B. monnieri* treatment promoted several anti-PD effects, including modulation of oxidative stress and nigrostriatal dopaminergic neuroprotection [249].

3.5.11. *Hibiscus asper*. The methanolic extract of the leaves of *Hibiscus asper* was used in an experimental model of PD in rats and proved to be neuroprotective, as it provided a significant increase in the activity of antioxidant enzymes (SOD, CAT, and GSH-Px) and decreased lipid peroxidation in the brain [250].

3.5.12. *Blackberries*. The ethanolic extract of blackberries was used in both *in vitro* and *in vivo* models of PD and demonstrated dose-dependent neuroprotective effects through anti-apoptotic and antioxidant effects [251].

3.5.13. *Eplingiella fruticosa*. *Eplingiella fruticosa* is a Brazilian aromatic plant used for pain treatment in Brazilian folk medicine, which has demonstrated potent antioxidant and anti-inflammatory properties. Beserra-Filho et al. [252] tested the essential oil obtained from *E. fruticosa* leaves against a reserpine-induced PD model in mice and demonstrated important anti-PD effects, such as modulation of oxidative stress, delayed onset of catalepsy, and protection against dopaminergic depletion in the striatum.

3.5.14. *Red Ginseng*. Ginseng treatment of rotenone-induced PD in rats promoted marked improvement of locomotor activity, suppression of β-amylloid deposition, and inhibition of the NF-κB inflammatory pathway and oxidative stress markers, and significantly increased tyrosine hydroxylase activity [253]. Moreover, *Angelica sinensis* extract, popularly known as "female ginseng," also prevented the occurrence of PD-like symptoms in a *C. elegans* model of the disease [254].

3.5.15. *Seaweeds*. Using the 6-OHDA-induced PD model in *SH-SY5Y* human neuroblastoma cells, several studies demonstrated promising anti-PD effects of seaweed extracts, such as brown seaweeds *Bifurcaria bifurcata* [255], *Ecklonia cava* [256], and *Sargassum hemiphyllum* [257], as well as the red seaweed *Chondrus crispus*, which was tested on the *C. elegans* model of PD [258].

3.6. Other Plant-Derived Molecules

3.6.1. *Diosgenin*. This natural steroid saponin extracted from the tubers of *Dioscorea* wild yam was used to prevent the alterations caused in the lipopolysaccharide- (LPS-) induced PD model in rats, resulting in a significant reduction in oxidative stress markers and inactivation of the Toll-like receptor (TLR)/NF-κB inflammatory pathway [259].

3.6.2. *Thymoquinone*. Extracted from the seeds of *Nigella sativa*, a plant popularly known as black cumin, thymoquinone is a bicyclic benzenoid ketone. It was employed by Ardah et al. [260] to prevent MPTP-induced PD in mice. Treatment with thymoquinone restored antioxidant enzymes, prevented lipid peroxidation, and attenuated the expression of proinflammatory cytokines.

3.6.3. *Sulforaphane*. It is an organic isothiocyanate extracted from many cruciferous vegetables, such as cabbages and broccoli. Bao et al. [261] investigated its effect on MPTP-induced damage in PC12 cells, reporting its ability to reduce Nrf2, HO-1, and nicotinamide quinine oxidoreductase, concluding that sulforaphane protected the cells via activation of the Nrf2-antioxidant responsive element pathway.

3.6.4. *Crocin*. Crocin, a saffron-active component, exhibited protective effects against malathion-induced PD in rats by reducing oxidative stress and anti-inflammatory effects and improving motor deficits and neurobehavioral impairments [262].

3.6.5. *Spermidine*. Spermidine is an antioxidant polyamine and was tested against rotenone-induced PD in rats,
reversing neuroinflammation and restoring striatal neurochemistry, as well as oxidative stress markers [263].

3.6.6. Gastrodin. It is the glucoside of gastrodinigen and has been isolated from the orchid Gastrodia elata. Haddadi et al. [264], using the 6-OHDA model of PD in rats, demonstrated catalepsy prevention and motor coordination in lesioned rats. Moreover, gastrodin suppressed MPO activity, lipid peroxidation, and NO synthesis induced by 6-OHDA and increased total antioxidant capacity in the substantia nigra pars compacta of these rats.

3.7. Drugs

3.7.1. Paroxetine. Using a mouse experimental model, Chung et al. [123] studied the effects of the antioxidant paroxetine in mice that received MPTP, demonstrating that this antidepressant drug protects nigrostriatal dopaminergic neurons from oxidative damage induced by the neurotoxin. Additionally, the authors also verified that paroxetine inhibited microglial activation and, therefore, the expression of iNOS and TNF-α; inhibited the activation of astroglia and hence the production of MPO; and promoted attenuation of the production of oxidizing agents via NADPH oxidase. Collectively, oxidative stress reduction has enabled the increase of dopamine levels in the nucleus striatum and the improvement of the motor performance of these animals.

3.7.2. Pramipexole. Pramipexole is a novel dopamine agonist that also inhibits oxidative stress and mitochondrial apoptosis. Wang et al. [265] used pramipexole transdermal patches (PPX) against MPTP-induced PD in mice, showing that PPX improved dyskinesias in PD-induced mice and restored the activity of antioxidant enzymes alongside MDA reduction. Another similar study demonstrated that PPX activates Akt kinase and, therefore, is related to SPHK1 activation, which is crucial for neurite extension in neurons and directed cell movement [266].

3.7.3. Simvastatin. Regularly employed to reduce cholesterol levels, this hydroxy-methyl-glutaryl-coenzyme A reductase inhibitor was tested against the 6-OHDA model of PD both in SH-SY5Y cells and mice, causing a reduction in oxidative markers, reversion of apoptosis, and inhibition of the mitogen-activated protein kinase (MAPK) pathway and NF-κB activation in SH-SY5Y cells. Simvastatin treatment in mice decreased limb asymmetry and apomorphine-induced rotations in PD mice [267].

3.7.4. Methylene Blue. Clinically used for a relatively long time, methylene blue is known for its neuroprotective and antioxidant properties. Focusing on the induction of neurotrophic factors, Bhurtel et al. [268] studied its effects against MPTP-induced PD in both in vivo and in vitro models of the disease. According to the authors, methylene blue treatment significantly reduced the loss of dopaminergic neurons, depletion of dopamine, and glial cell activation through the activation of brain-derived neurotrophic factor (BDNF).

3.7.5. Ebselen. MPTP was also used in a study performed in the primate model of PD to observe the action of ebselen, an antioxidant with actions similar to glutathione peroxidase. It was demonstrated that ebselen could prevent both the loss of neurons and the onset of clinical symptoms of the disease in this experimental model [269].

3.7.6. Geranylgeranylacetone. This synthetic drug used to treat gastric ulcers was associated with glial cell-derived neurotrophic factor against the MPTP-induced PD model in mice. Treated animals displayed significant recovery in their swim, pole, and traction scores, as well as reduced neuronal apoptosis in the substantia nigra and oxidative stress markers [270].

3.7.7. Lactoferrin. It is a non-heme iron-binding glycoprotein belonging to the transferrin family and was tested against the MPTP model of PD in mice. Beneficial effects on both the central and peripheral systems were observed, including a reduction in oxidative stress and neuronal apoptosis [51].

3.7.8. Apocynin. This well-known NADPH oxidase inhibitor was used by Hou et al. [271] to treat mice induced to PD by pesticide exposure (paraquat and maneb), causing significant improvement of mouse learning and memory deficits, effects associated with the inhibition of signal transducers and activators of transcription 1 (STAT1) and NF-κB pathways.

3.7.9. Norfluoxetine. Norfluoxetine is an active metabolite of the antidepressant fluoxetine that inhibits serotonin uptake. Treatment with norfluoxetine inhibited NADPH oxidase activation and nitrate production in microglial cell cultures and mitigated microglial cell activation and microglial-derived ROS production in the MPTP model of PD in mice [272].

3.7.10. Phenothiazine. It was formerly used as an insecticide and as a drug to treat infections with parasitic worms (anthelmintic) in livestock and humans and is the mother drug of modern antipsychotic drugs. Tapias et al. [273] used it against the rotenone-induced PD model in rats and rat midbrain cell cultures, demonstrating a significant reduction in protein thiol oxidation, mitochondrial dysfunction, axonal impairment, oxidative stress, and inflammatory response as a result of phenothiazine treatment.

3.7.11. Hydralazine. A potent Nrf2 activator, hydralazine was used by Guo et al. [274] against the MPTP-induced PD model in SH-SY5Y cells and mice, resulting in significant translocation of Nrf2, as well as upregulation of the expression of its downstream antioxidant genes. These effects resulted in substantial improvements in oxidative stress, behavioral disorders, and the loss of dopaminergic neurons in the substantia nigra and striatum of treated mice and cells, effects attributed to Nrf2 pathway activation.

3.8. Other Synthetic Molecules

3.8.1. Montelukast (MK). A cysteinyl leukotriene receptor antagonist, MK later exhibited remarkable neuroprotective activity in various neurodegenerative disorders. In the rotenone-induced PD animal model, MK exhibited neuroprotective effects through the attenuation of microglial cell
activation, oxidative stress inhibition, and p38 MAPK expression [275].

3.8.2. **DDO-7263.** A novel Nrf2-ARE activator, DDO-7263 was tested against MPTP-induced PD in mice, improving behavioral abnormalities induced by MPTP and significantly attenuating chemically induced dopaminergic neuron loss of tyrosine hydroxylase in the substantia nigra and striatum. In addition, DDO-7263 inhibited the secretion of inflammatory factors and protected PC12 neurons from H$_2$O$_2$-induced oxidative damage [276].

3.8.3. **KMS99220.** A synthetic morpholine-containing chalcone, KMS99220 confers neuroprotection due to its high binding affinity to the Nrf2 inhibitory protein Keap-1 and increased nuclear translocation of Nrf2 and gene expression of the antioxidant enzymes. It is reported to reduce α-synuclein aggregates in GFp-α-syn A53T-overexpressing cells, and in MPTP-treated mice, oral administration of KMS99220 prevented degeneration of the nigral dopaminergic neurons, induced the Nrf2 target genes, and effectively prevented the associated motor deficits [277].

3.8.4. **M40403.** A SOD-mimetic compound, it was employed with positive results in cellular and fly models of PD to reverse PD symptoms in PINK1 and Parkin phenotypes, which are known to be associated with early-onset forms of PD [278].

3.9. **Use of Nanoparticles to Deliver Antioxidants.** Another interesting method of antioxidant treatment in PD consists of delivering antioxidant molecules through nanoparticles that can direct antioxidant effects towards specific sites of the cell or that display specific scavenging activities.

3.9.1. **Ceria Nanoparticles.** Ceria nanoparticles effectively scavenge ROS, present catalase- and SOD-mimetic activities, and readily penetrate the cellular membrane and scavenge intracellular ROS in the cytosol. Moreover, triphenylphosphonium-conjugated ceria nanoparticles can scavenge mitochondrial ROS after their delivery to mitochondria. Extracellular ROS can also be scavenged through 300 nm sized ceria nanoparticle clusters that are not subject to cellular uptake. Kwon et al. [279] used ceria nanoparticles to treat PD-like symptoms in the MPTP model of PD in mice, reporting inhibition of lipid peroxidation and protection of tyrosine hydroxylase in the striatum of treated mice.

3.9.2. **Chitosan Nanoparticles.** Raj et al. [280] used chitosan nanoparticles to deliver the PD drug pramipexole by the intranasal route to rotenone-induced PD rats, reporting enhanced antioxidant status and increased dopamine levels in treated animals.

3.9.3. **Nanoemulsions.** Nanoemulsions were also tested to deliver selegine (also known as L-deprenyl, a medication that is used in the treatment of PD), displaying high antioxidant properties that, along with the anti-PD effects of selegine, conferred significant protection to treated rats [281].

4. **Final Remarks**

The use of antioxidants as adjuvant PD therapy has been debated because the results of the efficacy of antioxidant substances are not yet fully clarified in human studies. Nevertheless, although there is no clarity regarding the efficacy of antioxidant use in PD patients, Agim and Cannon [282] point out that dietary components may act as protective factors in PD, as demonstrated in both *in vivo* and *in vitro* studies.

Indeed, as presented in the numerous reports cited in this review, *in vitro* studies and animal models provide vast and strong evidence for the benefits of antioxidant supplementation to treat PD and set a solid ground for its use in human studies.

Among the several antioxidant approaches reported, antioxidants derived from plants have presented remarkable results, especially those with high flavonoid content, such as purple and red fruits and seaweeds.

In this sense, Joseph et al. [283] believe that antioxidant-rich foods may benefit neurons during neuronal aging, reversing or delaying free radical action, which are normally produced by dopaminergic neurons of the substantia nigra of the brain.

Nevertheless, it is worth noting that free radicals exert several beneficial roles in mammalian cells, such as ATP production, phagocytosis, and cell signaling [82], and the indiscriminate use of antioxidants might be harmful.

In conclusion, oxidative stress plays a crucial role in the pathogenesis of Parkinson’s disease, either by external factors or individual intrinsic factors. Nevertheless, the effects of oxidative stress and other factors related to the disease have not been fully elucidated thus far, and further studies are still necessary in the search for the formulation of new drugs and for more efficient use of existing drugs. However, the potential benefit of antioxidant supplements as an adjuvant therapy for Parkinson’s disease is unquestionable and is aimed at improving patient quality of life.

**Abbreviations**

- 6-OHDA: 6-Hydroxydopamine
- 8-OHdG: 8-Hydroxy-2-deoxyguanosine
- AA: Asiatic acid
- BDNF: Brain-derived neurotrophic factor
- BH4: Tetrahydrobiopterin
- CAT: Catalase
- Cl$: Chloride ion
- COMT: Catechol-O-methyltransferase
- CoQ$_{10}$: Coenzyme Q$_{10}$
- COX-2: Cyclooxygenase-2
- DHA: Docosahexanoic acid
- DHLA: Dihydrolipoic acid
- DOPAC: Dihydroxyphenylacetic acid
- EP: Ethyl pyruvate
- Fe$^{2+}$: Ferrous ion
- G6PD: Glucose-6-phosphate dehydrogenase
- GFAP: Glial fibrillary acidic protein
- GR: Glutathione reductase
- GRP75: Glucose-regulated protein 75
**Conflicts of Interest**

The authors declare no conflicts of interest.

**Acknowledgments**

The authors are grateful to Dr. Michael Dean Green for language revision. Funding was provided by the Federal University of Pará (UFPA).

**References**

[1] J. C. P. Limongi, *Conhecendo Melhor a Doença de Parkinson – Uma Abordagem Multidisciplinar com Orientações Práticas para o Dia-a-Dia*, Paxius, São Paulo, 2001.

[2] R. Savica, B. R. Grossardt, W. A. Rocca, and J. H. Bower, “Parkinson disease with and without dementia: a prevalence study and future projections,” *Movement Disorders*, vol. 33, no. 4, pp. 1–7, 2018.

[3] H. A. G. Teive and M. S. Meneses, “Histórico,” in *Doença de Parkinson: Aspectos Clínicos e Cirúrgicos*, M. S. Meneses and H. A. G. Teive, Eds., pp. 4–14, Guanabara Koogan, Rio de Janeiro, 1996.

[4] C. D. Silberman, J. Laks, C. S. Rodrigues, and E. Engelhardt, “A review of depression as a risk factor of Parkinson’s disease and impact cognition,” *Revista de Psiquiatria do Rio Grande do Sul*, vol. 26, no. 1, pp. 52–60, 2004.

[5] G. Genc, H. Abboud, S. Oravivattanakul et al., “Socioeconomic status may impact functional outcome of deep brain stimulation surgery in Parkinson’s disease,” *Neuromodulation*, vol. 19, no. 1, pp. 25–30, 2016.

[6] R. C. Lana, L. M. R. S. Álvare, C. Nasciutti-Prudente, F. R. P. Goulart, L. M. R. S. Álvare, C. Nasciutti-Prudente, F. R. P. Goulart, L. F. Teixeira-Salmela, and F. E. Cardoso, “Ablation of the inflammatory enzyme myeloperoxidase mitigates features of PD,” *Cerebrovascular and Brain Protection*, vol. 28, no. 4, pp. 195–210, 2008.

[7] M. P. Pisoschi and A. Pop, “The role of antioxidants in the chemistry of oxidative stress: a review,” *European Journal of Medicinal Chemistry*, vol. 97, pp. 55–74, 2015.

[8] G. T. Liberatore, V. Jackson-Lewis, S. Vukosavic et al., “Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease,” *Nature Medicine*, vol. 1409, 1999.

[9] J. C. P. Limongi, *Conhecendo Melhor a Doença de Parkinson – Uma Abordagem Multidisciplinar com Orientações Práticas para o Dia-a-Dia*, Paxius, São Paulo, 2001.

[10] R. Savica, B. R. Grossardt, W. A. Rocca, and J. H. Bower, “Parkinson disease with and without dementia: a prevalence study and future projections,” *Movement Disorders*, vol. 33, no. 4, pp. 1–7, 2018.

[11] H. A. G. Teive and M. S. Meneses, “Histórico,” in *Doença de Parkinson: Aspectos Clínicos e Cirúrgicos*, M. S. Meneses and H. A. G. Teive, Eds., pp. 4–14, Guanabara Koogan, Rio de Janeiro, 1996.

[12] C. D. Silberman, J. Laks, C. S. Rodrigues, and E. Engelhardt, “A review of depression as a risk factor of Parkinson’s disease and impact cognition,” *Revista de Psiquiatria do Rio Grande do Sul*, vol. 26, no. 1, pp. 52–60, 2004.

[13] G. Genc, H. Abboud, S. Oravivattanakul et al., “Socioeconomic status may impact functional outcome of deep brain stimulation surgery in Parkinson’s disease,” *Neuromodulation*, vol. 19, no. 1, pp. 25–30, 2016.

[14] R. C. Lana, L. M. R. S. Álvare, C. Nasciutti-Prudente, F. R. P. Goulart, L. F. Teixeira-Salmela, and F. E. Cardoso, “Ablation of the inflammatory enzyme myeloperoxidase mitigates features of PD,” *Cerebrovascular and Brain Protection*, vol. 28, no. 4, pp. 195–210, 2008.

[15] M. P. Pisoschi and A. Pop, “The role of antioxidants in the chemistry of oxidative stress: a review,” *European Journal of Medicinal Chemistry*, vol. 97, pp. 55–74, 2015.

[16] G. T. Liberatore, V. Jackson-Lewis, S. Vukosavic et al., “Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease,” *Nature Medicine*, vol. 1409, 1999.

[17] J. C. P. Limongi, *Conhecendo Melhor a Doença de Parkinson – Uma Abordagem Multidisciplinar com Orientações Práticas para o Dia-a-Dia*, Paxius, São Paulo, 2001.
Parkinson’s disease in mice,” *Journal of Neuroscience*, vol. 25, no. 28, pp. 6594–6600, 2005.

[14] M. Chalimoniuk, N. Lukacova, J. Marsala, and J. Langfort, “Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinsonism in mice,” *Neuroscience*, vol. 141, no. 2, pp. 1033–1046, 2006.

[15] C. Zhou, Y. Huang, and S. Przedborski, “Oxidative stress in Parkinson’s disease: a mechanism of pathogenic and therapeutic significance,” *Annals of the New York Academy of Sciences*, vol. 1147, pp. 93–104, 2008.

[16] R. A. Maki, M. Holzer, K. Motamedchaboki et al., “Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson’s disease and in the hMPO-α-synuclein-A53T mouse model, correlated with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment,” *Free Radical Biology and Medicine*, vol. 141, pp. 115–140, 2019.

[17] D. Rathnayake, T. Chang, and P. Udagama, “Selected serum cytokines and nitric oxide as potential multi-marker biomarker panels for Parkinson disease of varying durations: a case-control study,” *BMC Neurology*, vol. 19, no. 1, article 56, 2019.

[18] P. Jenner and C. W. Olanow, “Oxidative stress and the pathogenesis of Parkinson’s disease,” *Neurology*, vol. 47, 6, Supplement 3, pp. 1615S–1705S, 1996.

[19] T. B. Sherer, R. Betarbet, and J. T. Greenamyre, “Environment, mitochondria, and Parkinson’s disease,” *The Neuroscientist*, vol. 8, no. 3, pp. 192–197, 2002.

[20] J. Peng, L. Peng, F. F. Stevenson, S. R. Doctrow, and J. K. Andersen, “Iron and parquat as synergistic environmental risk factors in sporadic Parkinson’s disease accelerate age-related neurodegeneration,” *Journal of Neuroscience*, vol. 27, no. 26, pp. 6914–6922, 2007.

[21] Y. Zhou, M. Lu, R.-H. Du et al., “MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease,” *Molecular Neurodegeneration*, vol. 11, no. 1, p. 28, 2016.

[22] G. S. Gaki and A. G. Papavassiliou, “Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson’s disease,” *Neurochemical Medicine*, vol. 16, no. 2, pp. 217–230, 2014.

[23] L. H. You, F. Li, L. Wang et al., “Brain iron accumulation exacerbates the pathogenesis of MPTP-induced Parkinson’s disease,” *Neuroscience*, vol. 284, pp. 234–246, 2015.

[24] M. A. Tenkorang, P. Duong, and R. L. Cunningham, “NADPH oxidase mediates membrane androgen receptor-induced neurodegeneration,” *Endocrinology*, vol. 160, no. 4, pp. 947–963, 2019.

[25] O. Scudamore and T. Ciossek, “Increased oxidative stress exacerbates α-synuclein aggregation in vivo,” *Journal of Neuropathology & Experimental Neurology*, vol. 77, no. 6, pp. 443–453, 2018.

[26] R. E. Musgrove, M. Helwig, E.-J. Bae et al., “Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular α-synuclein transfer,” *The Journal of Clinical Investigation*, vol. 129, no. 9, pp. 3738–3753, 2019.

[27] S. Luo, S. S. Kang, Z. H. Wang et al., “Akt phosphorylates NQO1 and triggers its degradation, abolishing its antioxidative activities in Parkinson’s disease,” *Journal of Neuroscience*, vol. 39, no. 37, pp. 7291–7305, 2019.

[28] N. Sharma, S. P. Rao, and S. V. Kalivendi, “The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: role of oxidative stress mediated downregulation of DJ-1 in Parkinson’s disease,” *Free Radical Biology and Medicine*, vol. 135, pp. 28–37, 2019.

[29] I. Russo, A. Kaganovich, J. Ding et al., “Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils,” *Neurobiology of Disease*, vol. 129, pp. 67–78, 2019.

[30] H. Kuroská, K. Yamaguchi, K. Man-Yoshi, S. I. Muramatsu, S. Hara, and H. Ichinose, “Administration of tetrahydrobiopoterin restored the decline of dopamine in the striatum induced by an acute action of MPTP,” *Neurochemistry International*, vol. 125, pp. 16–24, 2019.

[31] M. Colamartino, G. Duranti, R. Ceci, S. Sabatini, A. Testa, and R. Cozzi, “A multi-biomarker analysis of the antioxidant efficacy of Parkinson’s disease therapy,” *Toxicology In Vitro*, vol. 47, pp. 1–7, 2018.

[32] C. Isole, T. Abe, and Y. Terayama, “Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson’s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process,” *Neuroscience Letters*, vol. 469, no. 1, pp. 159–163, 2010.

[33] J. Miletić, D. Drakulić, S. Pejić et al., “Prooxidant–antioxidant balance, advanced oxidation protein products and lipid peroxidation in Serbian patients with Parkinson’s disease,” *International Journal of Neuroscience*, vol. 128, no. 7, pp. 600–607, 2018.

[34] C. Vida, H. Kobayashi, A. Garrido et al., “Lymphoproliferation impairment and oxidative stress in blood cells from early Parkinson’s disease patients,” *International Journal of Molecular Sciences*, vol. 20, no. 3, p. 771, 2019.

[35] M. D. Ben, R. Bongiovanni, S. Tuniz et al., “Earliest mechanisms of dopaminergic neurons sufferance in a novel slow progressing ex vivo model of Parkinson disease in rat organotypic cultures of substantia nigra,” *International Journal of Molecular Sciences*, vol. 20, no. 9, p. 2224, 2019.

[36] C. C. de Farias, M. Maes, K. L. Bonifácio et al., “Highly specific changes in antioxidant levels and lipid peroxidation in Parkinson’s disease and its progression: disease and staging biomarkers and new drug targets,” *Neuroscience Letters*, vol. 617, pp. 66–71, 2016.

[37] Z. I. Alam, S. E. Daniel, A. J. Lees, D. C. Marsden, P. Jenner, and B. Halliwell, “A generalised increase in protein carbonyls in the brain in Parkinson’s but not incidental Lewy body disease,” *Journal of Neurochemistry*, vol. 69, no. 3, pp. 1326–1329, 1997.

[38] S. Abraham, C. C. Soundararajan, S. Vivekanandhan, and M. Behari, “Erythrocyte antioxidant enzymes in Parkinson’s disease,” *Indian Journal of Medical Research*, vol. 121, no. 2, pp. 111–115, 2005.

[39] C. Venkateshappa, G. Harish, R. B. Mythri, A. Mahadevan, M. M. S. Bharath, and S. K. Shankar, “Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson’s disease,” *Neurochemical Research*, vol. 37, no. 2, pp. 358–369, 2012.

[40] J. Fukae, Y. Mizuno, and N. Hattori, “Mitochondrial dysfunction in Parkinson’s disease,” *Mitochondrion*, vol. 7, no. 1–2, pp. 58–62, 2007.
[41] E. G. Moreira, D. Rial, A. S. Aguiar et al., "Proanthocyanidin-rich fraction from Croton celtidifolius Ball confers neuroprotection in the intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine rat model of Parkinson’s disease," *Journal of Neural Transmission*, vol. 117, no. 12, pp. 1337–1351, 2010.

[42] S. Ayton, P. Lei, D. J. Hare et al., "Parkinson’s disease iron deposition caused by nitric oxide-induced loss of β-amyloid precursor protein," *Journal of Neuroscience*, vol. 35, no. 8, pp. 3591–3597, 2015.

[43] J. M. Graham, M. N. Paley, R. A. Grünewald, N. Hoggard, and P. D. Griffiths, "Brain iron deposition in Parkinson’s disease imaged using the PRIME magnetic resonance sequence," *Brain*, vol. 123, no. 12, pp. 2423–2431, 2000.

[44] P. Costa-Mallen, C. Gatenby, S. Friend et al., "Brain iron concentrations in regions of interest and relation with serum iron levels in Parkinson disease," *Journal of the Neurological Sciences*, vol. 378, pp. 38–44, 2017.

[45] M. Fasano, B. Bergamasco, and L. Lopiano, "Is neuromelanin changed in Parkinson’s disease? Investigations by magnetic spectroscopies," *Journal of Neural Transmission*, vol. 113, no. 6, pp. 769–774, 2006.

[46] K. M. C. Chew, E.-T. Ang, Y. K. Tai et al., "Enhanced autophagy from chronic toxicity of iron and mutant A53T α-synuclein implications for neuronal cell death in Parkinson disease," *Journal of Biological Chemistry*, vol. 286, no. 38, pp. 33380–33389, 2011.

[47] H. Hochstrasser, J. Tomiuk, U. Walter et al., "Functional relevance of ceruloplasmin mutations in Parkinson’s disease," *The FASEB Journal*, vol. 19, no. 13, pp. 1851–1853, 2005.

[48] S. Olivieri, A. Conti, S. Iannaccone et al., "Ceruloplasmin oxidation, a feature of Parkinson’s disease CSF, inhibits ferroxi-dase activity and promotes cellular iron retention," *Journal of Neuroscience*, vol. 31, no. 50, pp. 18568–18577, 2011.

[49] B. N. Patel, R. J. Dunn, S. Y. Jeong, Q. Zhu, J. P. Julien, and S. David, "Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury," *Journal of Neuroscience*, vol. 22, no. 15, pp. 6578–6586, 2002.

[50] M. N. Karpenko, E. Y. Ilyicheva, Z. M. Muruzheva, I. V. Milyukhina, Y. A. Orlov, and L. V. Puchkova, "Role of copper dyshomeostasis in the pathogenesis of Parkinson’s disease," *Bulletin of Experimental Biology and Medicine*, vol. 164, no. 5, pp. 596–600, 2018.

[51] H. Liu, H. Wu, N. Zhu et al., "Lactoferrin protects against iron dysregulation, oxidative stress, and apoptosis in MPTP-induced Parkinson’s disease in mice," *Journal of Neurochemistry*, vol. 152, no. 3, pp. 397–415, 2019.

[52] B. Halliwell and J. M. C. Gutteridge, "Role of free radicals and catalytic metal ions in human disease: an overview," *Methods Enzymology*, vol. 186, pp. 1–85, 1999.

[53] N. B. Cole, D. D. Murphy, J. Lebowitz, L. Di Noto, L. R. Levine, and R. L. Nusbaum, "Metal-catalyzed oxidation of α-synuclein: helping to define the relationship between oligomers, prototibrils, and filaments," *Journal of Biological Chemistry*, vol. 280, no. 10, pp. 9678–9690, 2005.

[54] X. Zhang, W. Xie, S. Qu, T. Pan, X. Wang, and W. Le, "Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration," *Biochemical and Biophysical Research Communications*, vol. 333, no. 2, pp. 544–549, 2005.

[55] E. Carboni and P. Lingor, "Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson’s disease," *Metallomics*, vol. 7, no. 3, pp. 395–404, 2015.
chain and oxidative stress,” *Toxicology and Industrial Health,* vol. 26, no. 2, pp. 121–128, 2010.

[70] M. Marella, B. B. Seo, T. Yagi, and A. Matsuno-Yagi, “Parkinson’s disease and mitochondrial complex I: a perspective on the Nd11 therapy,” *Journal of Bioenergetics and Biomembranes,* vol. 41, no. 6, pp. 493–497, 2009.

[71] R. Betarbet, T. B. Sherer, G. Mackenzie, M. Garcia-Osuna, A. V. Panov, and J. T. Greenamyre, “Chronic systemic pesticide exposure reproduces features of Parkinson’s disease,” *Nature Neuroscience,* vol. 3, no. 12, pp. 1301–1306, 2000.

[72] T. B. Sherer, R. Betarbet, C. M. Testa et al., “Mechanism of toxicity in rotenone models of Parkinson’s disease,” *Journal of Neuroscience,* vol. 23, no. 34, pp. 10756–10764, 2003.

[73] S. R. Danielson, J. M. Held, M. Oo, R. Riley, B. W. Gibson, and J. K. Andersen, “Quantitative mapping of reversible mitochondrial Complex I cysteine oxidation in a Parkinson disease mouse model,” *Journal of Biological Chemistry,* vol. 286, no. 9, pp. 7601–7608, 2011.

[74] F. Wu, H. D. Xu, J. J. Guan et al., “Rotenone impairs autophagic flux and lysosomal functions in Parkinson’s disease,” *Neuroscience,* vol. 284, pp. 900–911, 2015.

[75] C. C. Chiu, T. H. Yeh, S. C. Lai et al., “Neuroprotective effects of aldehyde dehydrogenase 2 activation in rotenone-induced cellular and animal models of parkinsonism,” *Experimental Neurology,* vol. 263, pp. 244–253, 2015.

[76] A. P. Gatt, O. F. Duncan, J. Attems, P. T. Francis, C. G. Balard, and J. M. Bateman, “Dementia in Parkinson’s disease is associated with enhanced mitochondrial complex I deficiency,” *Movement Disorders,* vol. 31, no. 3, pp. 352–359, 2016.

[77] J. Jin, C. Hulette, Y. Wang et al., “Proteomic identification of a stress protein, mortalin/mhsp70/GRP75: relevance to Parkinson disease,” *Molecular & Cellular Proteomics,* vol. 5, no. 7, pp. 1193–1204, 2006.

[78] R. Wadhwa, J. Ryu, H. M. Ahn et al., “Functional significance of point mutations in stress chaperone mortalin and their relevance to Parkinson disease,” *Journal of Biological Chemistry,* vol. 290, no. 13, pp. 8447–8456, 2015.

[79] T. J. Cook, J. G. Hoekstra, D. L. Eaton, and J. Zhang, “Mortalin is expressed by astrocytes and decreased in the midbrain of Parkinson’s disease patients,” *Brain Pathology,* vol. 26, no. 1, pp. 75–81, 2016.

[80] M. A. Wilson, J. L. Collins, Y. Hod, D. Ringe, and A. G. Petsko, “The 1.1-Å resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson’s disease,” *Proceedings of the National Academy of Sciences,* vol. 100, no. 16, pp. 9256–9261, 2003.

[81] R. H. Kim, P. D. Smith, H. Aleyasin et al., “Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and oxidative stress,” *Proceedings of the National Academy of Sciences,* vol. 102, no. 14, pp. 5215–5220, 2005.

[82] H. Aleyasin, M. W. C. Rousseaux, M. Phillips et al., “The Parkinson’s disease gene DJ-1 is also a key regulator of stroke-induced damage,” *Proceedings of the National Academy of Sciences,* vol. 104, no. 47, pp. 18748–18753, 2007.

[83] J. Chen, L. Li, and L. S. Chin, “Parkinson disease protein DJ-1 converts from a zymogen to a protease by carboxyl-terminal cleavage,” *Human Molecular Genetics,* vol. 19, no. 12, pp. 2395–2408, 2010.

[84] I. Irrcher, H. Aleyasin, E. L. Seifert et al., “Loss of the Parkinson’s disease-linked gene DJ-1 perturbs mitochondrial dynamics,” *Human Molecular Genetics,* vol. 19, no. 19, pp. 3734–3746, 2010.

[85] W. Zhou, K. Bercury, J. Cummiskey, N. Luong, J. Lebin, and C. R. Freed, “Phenytoin up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease,” *Journal of Biological Chemistry,* vol. 286, no. 17, pp. 14941–14951, 2011.

[86] A. P. Joselin, S. J. Hewitt, S. M. Callaghan et al., “ROS-dependent regulation of Parkin and DJ-1 localization during oxidative stress in neurons,” *Human Molecular Genetics,* vol. 21, no. 22, pp. 4888–4903, 2012.

[87] N. Lev, Y. Barhum, N. S. Plisof et al., “DJ-1 protects against dopamine toxicity: implications for Parkinson’s disease and aging,” *The Journals of Gerontology Series A: Biological Sciences and Medical Sciences,* vol. 68, no. 3, pp. 215–225, 2013.

[88] L. Zondler, L. Miller-Fleming, M. Repici et al., “DJ-1 interactions with a-synuclein attenuate aggregation and cellular toxicity in models of Parkinson’s disease,” *Cell Death & Disease,* vol. 5, no. 7, p. e1350, 2014.

[89] R. M. Canet-Aviñol, M. A. Wilson, D. W. Miller et al., “The Parkinson’s disease protein DJ-1 is neuroprotective due to cysteine-sulfonic acid-driven mitochondrial localization,” *Proceedings of the National Academy of Sciences,* vol. 101, no. 24, pp. 9103–9108, 2004.

[90] W. Zhou and C. R. Freed, “DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T a-synuclein toxicity,” *Journal of Biological Chemistry,* vol. 280, no. 52, pp. 43150–43158, 2005.

[91] D. Steckley, M. Karajgikar, L. B. Dale et al., “Puma is a dominant regulator of oxidative stress induced Bax activation and neuronal apoptosis,” *Journal of Neuroscience,* vol. 27, no. 47, pp. 12989–12999, 2007.

[92] X. Qi, B. Davis, Y. H. Chang et al., “Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson’s disease model,” *Journal of Neurochemistry,* vol. 138, no. 5, pp. 746–757, 2016.

[93] J. Feng, C. Meng, and D. Xing, “Aβ induces PUMA activation: a new mechanism for Aβ-mediated neuronal apoptosis,” *Neurobiology of Aging,* vol. 36, no. 2, pp. 789–800, 2015.

[94] P.-C. Chen, M. R. Vargas, A. K. Pani et al., “Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson’s disease: critical role for the astrocyte,” *Proceedings of the National Academy of Sciences,* vol. 106, no. 8, pp. 2933–2938, 2009.

[95] R. E. Haskew-Layton, J. B. Payapilly, N. A. Smirnova et al., “Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway,” *Proceedings of the National Academy of Sciences,* vol. 107, no. 40, pp. 17385–17390, 2010.

[96] R. K. Dagda, S. J. Cherra, S. M. Kulich, A. Tandon, D. Park, and C. T. Chu, “Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fusion,” *Journal of Biological Chemistry,* vol. 284, no. 20, pp. 13843–13855, 2009.

[97] C. Cook, C. Stelter, and L. Petrucelli, “Disruption of protein quality control in Parkinson’s disease,” *Cold Spring Harbor Perspectives in Medicine,* vol. 2, no. 5, article a009423, 2012.

[98] M. Basso, J. Berlin, L. Xia et al., “Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation,” *Journal of Neuroscience,* vol. 32, no. 19, pp. 6561–6569, 2012.
Oxidative Medicine and Cellular Longevity

[99] P. Ghafourifar and C. A. Colton, "Mitochondria and nitric oxide," Antioxidants & Redox Signaling, vol. 5, no. 3, pp. 249-250, 2003.

[100] D. Yao, Z. Gu, T. Nakamura et al., "Nitrosative stress linked to sporadic Parkinson’s disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity," Proceedings of the National Academy of Sciences, vol. 101, no. 29, pp. 10810–10814, 2004.

[101] R. Kavya, R. Saluja, S. Singh, and M. Dikshit, "Nitric oxide synthase regulation and diversity: implications in Parkinson’s disease," Nitric Oxide, vol. 15, no. 4, pp. 280–294, 2006.

[102] S. H. Huh, Y. C. Chung, Y. Piao et al., "Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson’s disease," The Journal of Immunology, vol. 187, no. 2, pp. 960–969, 2011.

[103] P. K. K. Yeung, A. K. W. Lai, H. J. Son et al., "Aldose reductase deficiency leads to oxidative stress-induced dopaminergic neuronal loss and autophagic abnormality in an animal model of Parkinson’s disease," Neurobiology of Aging, vol. 50, pp. 119–133, 2017.

[104] J. S. Beckman and W. H. Koppenol, "Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly," American Journal of Physiology-Cell Physiology, vol. 271, no. 5, pp. C1424–C1437, 1996.

[105] T. Dehmer, J. Lindenauf, S. Haid, J. Dicgans, and J. B. Schulz, "Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo," Journal of Neurochemistry, vol. 74, no. 5, pp. 2213–2216, 2000.

[106] M. Bortolanza, R. Cavalcanti-Kiwiatkoski, F. E. Padovan-Neto et al., "Gial activation is associated with 1-DOPA induced dyskinesia and blocked by a nitric oxide synthase inhibitor in a rat model of Parkinson’s disease," Neurobiology of Disease, vol. 73, pp. 377–387, 2015.

[107] M. Ebadi and S. Sharma, "Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease," Experimental Biology and Medicine, vol. 231, no. 9, pp. 1576–1583, 2006.

[108] J. Lotharius, S. Barg, P. Wiekop, C. Lundberg, H. K. Raymon, and P. Brundin, "Effect of mutant α-synuclein on dopamine homeostasis in a new human mesencephalic cell line," Journal of Biological Chemistry, vol. 277, no. 41, pp. 38884–38894, 2002.

[109] L. Li, C.-W. Zhang, G. Y. J. Chen et al., "A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson’s disease models," Nature Communications, vol. 5, no. 1, article 3276, 2014.

[110] M. E. Gotz, G. Kunig, P. Riederer, and M. B. Youdim, "Oxidative stress: free radical production in neural degeneration," Pharmacology & Therapeutics, vol. 63, no. 1, pp. 37–122, 1994.

[111] L. F. Burbulla, P. Song, J. R. Mazzulli et al., "Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease," Science, vol. 357, no. 6357, pp. 1255–1261, 2017.

[112] M. Gesi, A. Santinami, and R. Ruffoli, "Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties)," Pharmacology & Toxicology: MiniReview, vol. 89, no. 5, pp. 217–224, 2001.

[113] A. H. Stokes, T. G. Hastings, and K. E. Vrana, "Cytotoxic and genotoxic potential of dopamine," Journal of Neuroscience Research, vol. 55, no. 6, pp. 659–665, 1999.

[114] S. B. Berman and T. G. Hastings, "Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species," Journal of Neurochemistry, vol. 69, no. 3, pp. 1185–1195, 1997.

[115] S. B. Berman and T. G. Hastings, "Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson’s disease," Journal of Neurochemistry, vol. 73, pp. 1127–1137, 1999.

[116] D. M. Kuhn, R. E. Arthur Junior, D. M. Thomas, and L. A. Ellerink, "Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson’s disease," Journal of Neurochemistry, vol. 73, no. 3, pp. 1309–1317, 1999.

[117] E. Sofic, K. W. Lange, K. Jellinger, and P. Riederer, "Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease," Neuroscience Letters, vol. 142, no. 2, pp. 128–130, 1992.

[118] J. Sian, D. T. D. Baxter, A. J. Lees et al., "Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia," Annals of Neurology, vol. 36, no. 5, pp. 348–355, 1994.

[119] P. Riederer, E. Sofic, and W. D. Rausch, "Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains," Journal of Neurochemistry, vol. 52, no. 2, pp. 515–520, 1989.

[120] F. Shang, M. Lu, E. Dudek, J. Reddan, and A. Taylor, "Vitamin C and vitamin E restore the resistance of GSH-depleted lens cells to H2O2," Free Radical Biology and Medicine, vol. 34, no. 5, pp. 521–530, 2003.

[121] J. A. Javitch, R. J. D’Amato, S. M. Stritmatter, and S. H. Snyder, "Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity," Proceedings of the National Academy of Sciences, vol. 82, no. 7, pp. 2173–2177, 1985.

[122] M. Moon, H. G. Kim, and L. Hwang, "Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease by blocking microglial activation," Neurotoxicity Research, vol. 15, no. 4, pp. 332–347, 2009.

[123] Y. C. Chung, S. R. Kim, and B. K. Jin, "Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson’s disease," The Journal of Immunology, vol. 185, no. 2, pp. 1230–1237, 2010.

[124] Y. C. Chung, E. Bok, S. H. Huh et al., "Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation," The Journal of Immunology, vol. 187, no. 12, pp. 6508–6517, 2011.

[125] M. E. Götz, A. Gerstner, R. Harth et al., "Altered redox state of platelet coenzyme Q10 in Parkinson’s disease," Journal of Neural Transmission, vol. 107, no. 1, pp. 41–48, 2000.

[126] J. Lan and D. H. Jiang, "Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson’s disease," Journal of Neural Transmission, vol. 104, no. 6-7, pp. 649–660, 1997.

[127] E. Sofic, W. Paulus, and K. Jellinger, "Selective increase of iron in substantia nigra zona compacta of parkinsonian brains," Journal of Neurochemistry, vol. 56, no. 3, pp. 978–982, 1991.
[128] S. Bharath, M. Hsu, D. Kaur, S. Rajagopalan, and J. K. Andersen, “Glutathione, iron and Parkinson’s disease,” Biochemical Pharmacology, vol. 64, no. 5–6, pp. 1037–1048, 2002.

[129] A. Yoritaka, N. Hattori, K. Uchida, M. Tanaka, E. R. Stadtmann, and Y. Mizuno, “Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease,” Proceedings of the National Academy of Sciences, vol. 93, no. 7, pp. 2696–2701, 1996.

[130] Z. I. Alam, A. Jenner, S. E. Daniel et al., “Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra,” Journal of Neurochemistry, vol. 69, no. 3, pp. 1196–1203, 1997.

[131] J. Campolo, R. De Maria, L. Cozzi et al., “Antioxidant and inflammatory biomarkers for the identification of prodromal Parkinson’s disease,” Journal of the Neurological Sciences, vol. 370, pp. 167–172, 2016.

[132] B. T. Zhu, “CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson’s disease,” International Journal of Molecular Medicine, vol. 13, no. 3, pp. 343–353, 2004.

[133] G. P. Paraskevas, E. Kapaki, O. Petropoulou, M. Anagnostoul, V. Vagenas, and C. Papageorgiou, “Plasma levels of antioxidant vitamins C and E are decreased in vascular parkinsonism,” Journal of the Neurological Sciences, vol. 215, no. 1–2, pp. 51–55, 2003.

[134] R. K. Chaturvedi, S. Shukla, K. Seth et al., “Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease,” Neurobiology of Disease, vol. 22, no. 2, pp. 421–434, 2006.

[135] J. H. Wei, M. Du, and Y. H. Bai, “Correlations of melatonin and glutathione levels with oxidative stress mechanism in Parkinson’s disease,” Acta Academiae Medicinae Sinicae, vol. 41, no. 2, pp. 183–187, 2019.

[136] M. A. Zampol and M. H. Barros, “Melatonin improves survival and respiratory activity of yeast cells challenged by alpha-synuclein and menadione,” Yeast, vol. 35, no. 3, pp. 281–290, 2018.

[137] G. Patki and Y. S. Lau, “Melatonin protects against neurobehavioral and mitochondrial deficits in a chronic mouse model of Parkinson’s disease,” Pharmacology Biochemistry and Behavior, vol. 99, no. 4, pp. 704–711, 2011.

[138] R. Paul, B. C. Phukan, A. J. Thenmozhi, T. Manivasagam, P. Bhattacharya, and A. Borah, “Melatonin protects against behavioral deficits, dopamine loss and oxidative stress in homocysteine model of Parkinson’s disease,” Life Sciences, vol. 192, pp. 238–245, 2018.

[139] Y. Li, S. M. Wang, L. Guo et al., “Effects of melatonin levels on neurotoxicity of the medial prefrontal cortex in a rat model of Parkinson’s disease,” Chinese Medical Journal, vol. 130, no. 22, p. 2726, 2017.

[140] M. Z. Rasheed, S. S. Andrabi, M. Salman et al., “Melatonin improves behavioral and biochemical outcomes in a rotenone-induced rat model of Parkinson’s disease,” Journal of Environmental Pathology, Toxicology and Oncology, vol. 37, no. 2, pp. 139–150, 2018.

[141] T. B. Bassani, R. W. Gradowski, T. Zaminelli et al., “Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson’s disease model in rats,” Brain Research, vol. 1593, pp. 95–105, 2014.

[142] O. Ozsoy, F. B. Yildirim, E. Ogut et al., “Melatonin is protective against 6-hydroxydopamine-induced oxidative stress in a hemiparkinsonian rat model,” Free Radical Research, vol. 49, no. 8, pp. 1004–1014, 2015.

[143] G. G. Ortiz, E. W. Morales-Sánchez, F. P. Pacheco-Moisés et al., “Effect of melatonin administration on cyclooxygenase-2 activity, serum levels of nitric oxide metabolites, lipoperoxides and glutathione peroxidase activity in patients with Parkinson’s disease,” Gaceta medica de Mexico, vol. 153, no. Supl. 2, Supplement 2, pp. 572–581, 2017.

[144] A. Naskar, V. Prabhakar, R. Singh, D. Dutta, and K. P. Mohanakumar, “Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice,” Journal of Pineal Research, vol. 58, no. 3, pp. 262–274, 2015.

[145] H. Belaid, J. Adrien, C. Karachi, E. C. Hirsch, and C. François, “Effect of melatonin on sleep disorders in a monkey model of Parkinson’s disease,” Sleep Medicine, vol. 16, pp. 1245–1251, 2015.

[146] X. Sun, D. Ran, X. Zhao et al., “Melatonin attenuates hLRKK2-induced sleep disturbances and synaptic dysfunction in a Drosophila model of Parkinson’s disease,” Molecular Medicine Reports, vol. 13, no. 5, pp. 3936–3944, 2016.

[147] G. A. Dowling, J. Mastick, E. Colling, J. H. Carter, C. M. Singer, and M. J. Aminoff, “Melatonin for sleep disturbances in Parkinson’s disease,” Sleep Medicine, vol. 6, no. 5, pp. 459–466, 2005.

[148] M. Gilat, A. C. Jackson, N. S. Marshall et al., “Melatonin for rapid eye movement sleep behavior disorder in Parkinson’s disease: a randomised controlled trial,” Movement Disorders, vol. 35, no. 2, pp. 344–349, 2020.

[149] J. H. Ahn, M. Kim, S. Park et al., “Prolonged-release melatonin in Parkinson’s disease patients with a poor sleep quality: a randomized trial,” Parkinsonism & Related Disorders, vol. 16, pp. 50–54, 2020.

[150] W. Zhang, X. Y. Chen, S. W. Su et al., “Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials,” Neurological Sciences, vol. 37, no. 1, pp. 57–65, 2016.

[151] M. Ebadi, P. Govirapong, S. Sharma, D. Murukrishnan, S. Shavali, and L. Pellett, “Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of Parkinson’s disease,” Neurosignals, vol. 10, no. 3–4, pp. 224–253, 2001.

[152] R. A. Bonakdar and E. Guarnieri, “Coenzyme Q10,” American Family Physician, vol. 72, no. 6, pp. 1065–1070, 2005.

[153] K. S. Echtay, D. Roussel, J. St-Pierre, M. B. Jekabsons, S. Cadenas, and J. A. Stuart, “Superoxide activates mitochondrial uncoupling proteins,” Nature, vol. 415, no. 6867, pp. 96–99, 2002.

[154] R. T. Matthews, L. Yang, S. Browne, M. Baik, and M. F. Beal, “Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects,” Proceedings of the National Academy of Sciences, vol. 95, no. 15, pp. 8892–8897, 1998.

[155] A. A. Abdin and H. E. Hamouda, “Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism,” Neuropharmacology, vol. 55, pp. 1340–1346, 2008.

[156] C. Cleren, L. Yang, B. Lorenzo et al., “Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinson’s disease,” Parkinsonism & Related Disorders, vol. 21, no. 7, pp. 262–274, 2015.
model of parkinsonism,” *Journal of Neurochemistry*, vol. 104, pp. 113–1621, 2008.

[157] M. F. Beal, R. T. Matthews, A. Tiedeman, and C. W. Shulats, “Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice,” *Brain Research*, vol. 783, no. 1, pp. 109–114, 1998.

[158] T. L. Horvath, S. Diano, C. Leranth et al., “Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson’s disease,” *Endocrinology*, vol. 144, no. 7, pp. 2757–2760, 2003.

[159] S. K. Sharma, H. El ReFaey, and M. Ebadi, “Complex-I activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson’s disease and the neuroprotective role of coenzyme Q10,” *Brain Research Bulletin*, vol. 70, pp. 22–32, 2006.

[160] The Parkinson’s Study Group Q3, “A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease. No evidence of benefit,” *JAMA Neurology*, vol. 71, pp. 543–552, 2014.

[161] A. Negida, A. Menshawy, G. El Ashal et al., “Coenzyme Q10 for patients with Parkinson’s disease: a systematic review and meta-analysis,” *CNS & Neurological Disorders – Drug Targets*, vol. 15, pp. 45–53, 2016.

[162] M. Cortese, T. Riise, A. Engeland, A. Ascherio, and K. Bjørnevik, “Urate and the risk of Parkinson’s disease in men and women,” *Parkinsonism & Related Disorders*, vol. 52, pp. 76–82, 2018.

[163] M. R. Sarukhani, H. Haghdoost-Yazdi, and G. Khandan-Celelarc, “Changes in the serum urate level can predict the development of Parkinsonism in the 6-hydroxydopamine animal model,” *Neurochemical Research*, vol. 43, no. 5, pp. 1086–1095, 2018.

[164] E. J. C. M. Coolen, I. C. W. Arts, O. Bekers, C. Vervaet, A. Bast, and P. C. Dagnelie, “Oral bioavailability of ATP after prolonged administration,” *British Journal of Nutrition*, vol. 105, no. 3, pp. 357–366, 2011.

[165] E. Andreadou, C. Nikolaou, F. Gournaras et al., “Serum uric acid levels in patients with Parkinson’s disease: their relationship to treatment and disease duration,” *Clinical Neurology and Neurosurgery*, vol. 111, no. 9, pp. 724–728, 2009.

[166] A. Nakashima, A. Yamauchi, J. Matsumoto et al., “Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson’s disease,” *Behavioural Pharmacology*, vol. 30, no. 1, pp. 89–94, 2019.

[167] T. T. Huang, D. L. Hao, B. N. Wu, L. L. Mao, and J. Zhang, “Uric acid demonstrates neuroprotective effect on Parkinson’s disease mice through Nrf2-ARE signaling pathway,” *Biochemical and Biophysical Research Communications*, vol. 493, no. 4, pp. 1443–1449, 2017.

[168] H. Iwaki, R. Ando, N. Miyae et al., “One year safety and efficacy of inosine to increase the serum urate level for patients with Parkinson’s disease in Japan,” *Journal of the Neurological Sciences*, vol. 385, pp. 75–78, 2017.

[169] E. Verdini, “NAD” in aging, metabolism, and neurodegeneration,” *Science*, vol. 350, no. 6265, pp. 1208–1213, 2015.

[170] C. Shan, Y. L. Gong, Q. Q. Zhuang et al., “Protective effects of β-nicotinamide adenine dinucleotide against motor deficits and dopaminergic neuronal damage in a mouse model of Parkinson’s disease,” *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 94, p. 109670, 2019.

[171] F. S. Ferreira, H. Biasibetti-Brendler, P. Pierozan et al., “Kynurenic acid restores Nrf2 levels and prevents quinolinic acid-induced toxicity in rat striatal slices,” *Molecular Neurobiology*, vol. 55, no. 11, pp. 8538–8549, 2018.

[172] E. L. Gill, S. Raman, R. A. Yost, T. J. Garrett, and V. Vedamai, “L-Carnitine inhibits lipopolysaccharide-induced nitric oxide production of SIM-A9 microglia cells,” *ACS Chemical Neuroscience*, vol. 9, no. 5, pp. 901–905, 2018.

[173] Y. Zhao, Q. Wang, Y. Wang, J. Li, G. Lu, and Z. Liu, “Glutamine protects against oxidative stress injury through inhibiting the activation of PI3K/Akt signaling pathway in parkinsonian cell model,” *Environmental Health and Preventive Medicine*, vol. 24, no. 1, pp. 1–7, 2019.

[174] S. Hernandez, C. Requejo, E. Herran et al., “Beneficial effects of n-3 polysaturated fatty acids administration in a partial lesion model of Parkinson’s disease: the role of glia and Nrf2 regulation,” *Neurobiology of Disease*, vol. 121, pp. 252–262, 2019.

[175] L. Packer, E. H. Witt, and H. J. Tritschler, “Alpha-lipoic acid as a biological antioxidant,” *Free Radical Biology and Medicine*, vol. 19, no. 2, pp. 227–250, 1995.

[176] L. Packer, H. J. Tritschler, and K. Wessel, “Neuroprotection by the metabolic antioxidant α-lipoic acid,” *Free Radical Biology and Medicine*, vol. 22, no. 1-2, pp. 359–378, 1997.

[177] A. Maczurek, K. Hager, M. Kenkliès, M. Sharan, R. Martins, and J. Engel, “Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer’s disease,” *Advanced Drug Delivery Reviews*, vol. 60, no. 13-14, pp. 1463–1470, 2008.

[178] A. Bilska, M. Dubiel, M. Sokolowska-Jez-iewicz, E. Lorenc-koci, and L. Włodek, “Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex of rat brain,” *Neuroscience*, vol. 146, no. 4, pp. 1758–1771, 2007.

[179] B. Zhou, M. Wen, X. Lin et al., “Alpha lipoamide ameliorates motor deficits and mitochondrial dynamics in the Parkinson’s disease model induced by 6-hydroxydopamine,” *Neurotoxicity Research*, vol. 33, no. 4, pp. 759–767, 2018.

[180] L. Zhou and Y. Cheng, “Alpha-lipoic acid alleviated 6-OHDA-induced cell damage by inhibiting AMPK/mTOR mediated autophagy,” *Neuropharmacology*, vol. 155, pp. 98–103, 2019.

[181] O. I. Kulikova, D. S. Berezhnoy, S. L. Stvolinsky, A. V. Lopachev, V. S. Orlova, and T. N. Fedorova, “Neuroprotective effect of the carnosine–α-lipoic acid nanomicellar complex in a model of early-stage Parkinson’s disease,” *Regulatory Toxicology and Pharmacology*, vol. 95, pp. 254–259, 2018.

[182] S. F. Zhang, C. L. Xie, J. Y. Lin, M. H. Wang, X. J. Wang, and Z. G. Liu, “Lipoic acid alleviates L-DOPA-induced dyskinesia in 6-OHDA parkinsonian rats via anti-oxidative stress,” *Molecular Medicine Reports*, vol. 17, no. 1, pp. 1118–1124, 2018.

[183] A. A. Abdin and N. I. Sarhan, “Intervention of mitochondrial dysfunction-oxidative stress-dependent apoptosis as a possible neuroprotective mechanism of α-lipoic acid against rotenone-induced parkinsonism and l-dopa toxicity,” * Neuroscience Research*, vol. 71, pp. 387–395, 2011.

[184] U. J. Dumaswala, L. Zhuo, S. Mahajan et al., “Glutathione protects chemokine-scavenging and antioxidative defense functions in human RBCs,” *American Journal of Physiology-Cell Physiology*, vol. 280, no. 4, pp. C867–C873, 2001.
A. Virel, I. Dudka, R. Laterveer, and S. af Bjerkén, “Human TNF-α in transgenic mice induces differential changes in redox status and glutathione-regulating enzymes,” The FASEB Journal, vol. 16, no. 11, pp. 1450–1452, 2002.

N. Yamamoto, H. Sawada, Y. Izumi et al., “Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease,” Journal of Biological Chemistry, vol. 282, no. 7, pp. 4364–4372, 2007.

G. Harish, C. Venkateshappa, R. B. Mythri et al., “Bioconjugates of curcumin display improved protection against glutathione depletion mediated oxidative stress in a dopaminergic neuronal cell line: implications for Parkinson’s disease,” Bioorganic & Medicinal Chemistry, vol. 18, no. 7, pp. 2631–2638, 2010.

D. Shen, T. P. Dalton, D. W. Nebert, and H. G. Shertzer, “Glutathione redox state regulates mitochondrial reactive oxygen production,” Journal of Biological Chemistry, vol. 280, no. 27, pp. 25305–25312, 2005.

N. Jha, O. Jurma, G. Lalli, Y. Liu, E. H. Pettus, and J. T. Greenamyre, “Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity implications for Parkinson’s disease,” Journal of Biological Chemistry, vol. 275, no. 34, pp. 26096–26101, 2000.

S. J. Chinta, M. J. Kumar, M. Hsu, S. Rajagopalan, D. Kaur, and A. Rane, “Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration,” Journal of Neuroscience, vol. 27, no. 51, pp. 13997–14006, 2007.

J. B. Schulz, J. Lindenau, J. Seyfried, and J. Dichgans, “Glutathione, oxidative stress and neurodegeneration,” European Journal of Biochemistry, vol. 267, no. 16, pp. 4904–4911, 2000.

G. Sechi, M. G. Deledda, G. Bua et al., “Reduced intraventricular glutathione in the treatment of early Parkinson’s disease,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 20, no. 7, pp. 1159–1170, 1996.

M. Yamamoto, N. Sakamoto, A. Iwai et al., “Protective actions of YM737, a new glutathione analog, against cerebral ischemia in rats,” Research Communications in Chemical Pathology and Pharmacology, vol. 81, no. 2, pp. 221–232, 1993.

R. Wassef, R. Haenold, A. Hansel, N. Brot, S. H. Heinemann, and T. Hoshi, “Methionine sulfoxide reductase A and a dietary supplement S-methyl-L-cysteine prevent Parkinson’s-like symptoms,” Journal of Neuroscience, vol. 27, no. 47, pp. 12808–12816, 2007.

J. Clark, E. L. Clore, K. Zheng, A. Adame, E. Masliah, and D. K. Simón, “Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in α-synuclein overexpressing mice,” PLoS One, vol. 5, no. 8, pp. 1–10, 2010.

M. Sarukhani, H. Haghdoost-Yazdi, A. Sarbazi Golezari, A. Babayan-Tazekhand, T. Dargahi, and N. Rastgoo, “Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson’s disease: behavioral, histological and biochemical studies,” Neurological Research, vol. 40, no. 7, pp. 523–531, 2018.

A. Virel, I. Dudka, R. Laterveer, and S. af Bjerkén, “1H NMR profiling of the 6-OHDA parkinsonian rat brain reveals metabolic alterations and signs of recovery after N-acetylcysteine treatment,” Molecular and Cellular Neuroscience, vol. 98, pp. 131–139, 2019.

A. R. Bonilla-Porras, M. Jimenez-Del-Rio, and C. Velez-Pardo, “N-Acetyl-cysteine blunts 6-hydroxydopamine-and 1-buthionine-sulfoximine-induced apoptosis in human mesenchymal stromal cells,” Molecular Biology Reports, vol. 46, no. 4, pp. 4423–4435, 2019.

L. D. Coles, P. J. Tuite, G. Öz et al., “Repeated-dose oral N-acetylcysteine in Parkinson’s disease: pharmacokinetics and effect on brain glutathione and oxidative stress,” The Journal of Clinical Pharmacology, vol. 58, no. 2, pp. 158–167, 2018.

Y. Miyake, W. Fukushima, K. Tanaka et al., “ Dietary intake of antioxidant vitamins and risk of Parkinson’s disease: a case-control study in Japan,” European Journal of Neurology, vol. 18, no. 1, pp. 106–113, 2011.

M. C. de Rijk, M. M. B. Breteler, J. H. den Breeijen et al., “ Dietary antioxidants and Parkinson disease: the Rotterdam Study,” Archives of Neurology, vol. 54, no. 6, pp. 762–765, 1997.

S. M. Zhang, M. A. Herman, H. Chen, D. Spiegelman, W. C. Willett, and A. Ascherio, “Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk,” Neurology, vol. 59, no. 8, pp. 1161–1169, 2002.

M. Etminan, S. S. Gill, and A. Samii, “Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis,” The Lancet Neurology, vol. 4, no. 6, pp. 362–365, 2005.

T. Schirinzi, G. Martella, P. Imbriani et al., “Dietary vitamin E as a protective factor for Parkinson’s disease: clinical and experimental evidence,” Frontiers in Neurology, vol. 10, 2019.

K. Kieburtz, M. McDermott, P. Como et al., “The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson’s disease,” Neurology, vol. 44, no. 9, pp. 1756–1759, 1994.

D. M. Morens, A. Grandinetti, C. I. Waslien, C. B. Park, G. W. Ross, and L. R. White, “Case-control study of idiopathic Parkinson’s disease and dietary vitamin E intake,” Neurology, vol. 46, no. 5, pp. 1270–1270, 1996.

W. L. Scheider, L. A. Hershey, J. E. Vena, T. Holmlund, J. R. Marshall, and J. L. Freundeman, “Dietary antioxidants and other dietary factors in the etiology of Parkinson’s disease,” Movement Disorders, vol. 12, no. 2, pp. 190–196, 1997.

C. Anderson, H. Checkoway, G. M. Franklin, S. Beresford, T. Smith-Weller, and P. D. Swanson, “Dietary factors in Parkinson’s disease: the role of food groups and specific foods,” Movement Disorders, vol. 14, no. 1, pp. 21–27, 1999.

W. Hellenbrand, H. Boeing, B. P. Robra et al., “Diet and Parkinson’s disease. I. A possible role for the past intake of specific nutrients. Results from a self-administered food-frequency questionnaire in a case-control study,” Neurology, vol. 47, no. 3, pp. 644–650, 1996.

K. C. Hughes, X. Gao, I. Y. Kim et al., “Intake of antioxidant vitamins and risk of Parkinson’s disease,” Movement Disorders, vol. 31, no. 12, pp. 1909–1914, 2016.

K. Ono and M. Yamada, “Vitamin A potently destabilizes preformed α-synuclein fibrils in vitro: implications for Lewy body diseases,” Neurobiology of Disease, vol. 25, no. 2, pp. 446–454, 2007.

S. Fahn, “A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson’s disease,” Annals of Neurology, vol. 32, no. S1, pp. S128–S132, 1992.

M. Roghani and G. Behzadi, “Neuroprotective effect of vitamin E on the early model of Parkinson’s disease in rat: Oxidative Medicine and Cellular Longevity...
behavioral and histochemical evidence,” Brain Research, vol. 892, no. 1, pp. 211–217, 2001.

[114] J. C. Garcia-Moreno, M. P. de la Riva, E. Martinez-Lara, E. Siles, and A. Cañuelo, “Tyrosol, a simple phenol from EVOO, targets multiple pathogenic mechanisms of neurodegeneration in a C. elegans model of Parkinson’s disease,” Neurobiology of Aging, vol. 82, pp. 60–68, 2019.

[115] J. Ren, L. Yuan, W. Wang et al., “Tricetin protects against 6-OHDA-induced neurotoxicity in Parkinson’s disease model by activating Nrf2/ARE signaling pathway and preventing mitochondria-dependent apoptosis pathway,” Toxicology and Applied Pharmacology, vol. 378, article 114617, 2019.

[116] A. T. R. Goes, C. R. Jesse, M. S. Antunes et al., “Protective role of chrysosin on 6-hydroxydopamine-induced neurodegeneration a mouse model of Parkinson’s disease: involvement of neuroinflammation and neurotrophins,” Chemico-Biological Interactions, vol. 279, pp. 111–120, 2018.

[117] A. Krishnamoorthy, M. Sevanan, S. Mani, M. Balu, S. Balaji, and R. P, “Chrysosin restores MPTP induced neuroinflammation, oxidative stress and neurotrophic factors in an acute Parkinson’s disease model mouse,” Neuroscience Letters, vol. 709, article 134382, 2019.

[118] M. Li, F. Zhou, T. Xu, H. Song, and B. Lu, “Acteoside protects against 6-OHDA induced dopaminergic neuron damage via Nrf2-ARE signaling pathway,” Food and Chemical Toxicology, vol. 119, pp. 6–13, 2018.

[119] C. Li, B. Tang, Y. Feng et al., “Pinostrobin exerts neuroprotective actions in neurotoxin-induced Parkinson’s disease models through Nrf2 induction,” Journal of Agricultural and Food Chemistry, vol. 66, no. 31, pp. 8307–8318, 2018.

[120] Y. L. Wang, B. Ju, Y. Z. Zhang et al., “Protective effect of curcumin against oxidative stress-induced injury in rats with Parkinson’s disease through the Wnt/β-catenin signaling pathway,” Cellular Physiology and Biochemistry, vol. 43, no. 6, pp. 2226–2241, 2017.

[121] T. T. Nguyen, M. D. Vuu, M. A. Huynh, M. Yamaguchi, T. I. Tran, and T. P. T. Dang, “Curcumin effectively rescued Parkinson’s disease-like phenotypes in a novel Drosophila melanogaster model with DUCH knockdown,” Oxidative Medicine and Cellular Longevity, vol. 2018, Article ID 2038267, 12 pages, 2018.

[122] M. Ramkumar, S. Rajasanakur, J. W. Swaminathan, K. Prabu, and G. V. Venkatesh, “Demethoxycurcumin ameliorates rotenone-induced toxicity in rats,” Frontiers in Bioscience (Elite Edition), vol. 11, pp. 1–11, 2019.

[123] M. R. Poetini, S. M. Araujo, M. T. de Paula et al., “Hesperidin attenuates iron-induced oxidative damage and dopamine depletion in Drosophila melanogaster model of Parkinson’s disease,” Chemico-Biological Interactions, vol. 279, pp. 177–186, 2018.

[124] S. Mani, S. Sekar, R. Barathidasan et al., “Naringenin decreases α-synuclein expression and neuroinflammation in MPTP-induced Parkinson’s disease model in mice,” Neurotoxicity Research, vol. 33, no. 3, pp. 656–670, 2018.

[125] M. Sugumar, M. Sevanan, and S. Sekar, “Neuroprotective effect of naringenin against MPTP-induced oxidative stress,” International Journal of Neuroscience, vol. 129, no. 6, pp. 534–539, 2019.

[126] L. F. Zhang, X. L. Yu, M. Ji et al., “Resveratrol alleviates motor and cognitive deficits and neuropathology in the A53T α-synuclein mouse model of Parkinson’s disease,” Food & Function, vol. 9, no. 12, pp. 6414–6426, 2018.

[127] A. O. Abolaji, A. O. Adedara, M. A. Adie, M. Vicente-Crespo, and E. O. Farombi, “Resveratrol prolongs lifespan and improves 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced oxidative damage and behavioural deficits in Drosophila melanogaster,” Biochemical and Biophysical Research Communications, vol. 503, no. 2, pp. 1042–1048, 2018.
"Neuroprotective effect of a standardized extract of Centella asiatica ECA233 in rotenone-induced parkinsonism rats," *Phytomedicine*, vol. 44, pp. 65–73, 2018.

[241] S.-Y. Park, G. Karthivashan, H. M. Ko et al., “Aqueous extract of Dendropanax morbillus leaves effectively alleviated neuroinflammation and behavioral impediments in MPTP-induced Parkinson’s mouse model,” *Oxidative Medicine and Cellular Longevity*, vol. 2018, Article ID 3175214, 14 pages, 2018.

[242] X. Xiang, L. Wu, L. Mao, and Y. Liu, “Anti-oxidative and anti-apoptotic neuroprotective effects of Azadirachta indica in Parkinson-induced functional damage,” *Molecular Medicine Reports*, vol. 17, no. 6, pp. 7959–7965, 2018.

[243] V. Singh, M. M. Essa, N. Guizani et al., “Protective effect of Zizyphus spinachristi on MPP+-induced oxidative stress,” *Frontiers in Bioscience*, vol. 10, pp. 285–299, 2018.

[244] P. Chonpathompikunlert, P. Boonruamkaew, W. Sukketsiri, D. P. de Araújo, P. C. N. Nogueira, A. D. C. Santos et al., “Olea europaea extract of olive (Parkinson disease, no. 1, pp. 79–88, 2018.

[245] J. I. A. Beserra-Filho, A. M. de Macêdo, A. H. F. F. Leão et al., “β-Synuclein transgenic mouse models of Parkinson disease in rats,” *Neurochemistry International*, vol. 116, pp. 104–111, 2018.

[246] B. Motyl, L. and its ameliorative effect on MPTP-induced Parkinson-like symptoms in mice," BMC Complementary and Alternative Medicine, vol. 18, no. 1, p. 103, 2018.

[247] P. Rojas, S. Montes, N. Serrano-Garcia, and J. Rojas-Castañeda, “Effect of EGB761 supplementation on the content of copper in mouse brain in an animal model of Parkinson’s disease,” *Nutrition*, vol. 25, no. 4, pp. 482–485, 2009.

[248] S. Kuang, L. Yang, Z. Rao et al., “Effects of Ginkgo biloba extract on A53T α-synuclein transgenic mouse models of Parkinson’s disease,” *Canadian Journal of Neurological Sciences*, vol. 45, no. 2, pp. 182–187, 2018.

[249] D. P. de Araújo, P. C. N. Nogueira, A. D. C. Santos et al., “Aspidosperma pyrifolium Mart: neuroprotective, antioxidant and anti-inflammatory effects in a Parkinson’s disease model in rats,” *Journal of Pharmacy and Pharmacology*, vol. 70, no. 6, pp. 787–796, 2018.

[250] M. Sarbishegi, E. A. C. Gorgich, O. Khajavi, G. Komeili, and P. Chonpathompikunlert, P. Boonruamkaew, W. Sukketsiri, D. P. de Araújo, P. C. N. Nogueira, A. D. C. Santos et al., “Olea europaea extract of olive (Parkinson disease, no. 1, pp. 79–88, 2018.

[251] H. G. Kim, M. S. Ju, J. S. Shim et al., “Mulberry fruit protects dopaminergic neurons in toxin-induced Parkinson’s disease models,” *British Journal of Nutrition*, vol. 104, no. 1, pp. 8–16, 2010.

[252] J. A. Beserra-Filho, A. M. de Macêdo, A. H. F. F. Leão et al., “Epilobium fruticosus leaf essential oil complexed with β-cyclodextrin produces a superior neuroprotective and behavioral profile in a mice model of Parkinson’s disease,” *Food and Chemical Toxicology*, vol. 124, pp. 17–29, 2019.

[253] M. A. Zaafan, A. M. Abdelhamid, and S. M. Ibrahim, “The protective effect of Korean red ginseng against rotenone-induced Parkinson’s disease in rat model: modulation of nuclear factor-κB and caspase-3,” *Current Pharmaceutical Biotechnology*, vol. 20, no. 7, pp. 588–594, 2019.

[254] R.-H. Fu, H.-J. Harn, S.-P. Liu et al., “n-Butyldenediphthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson’s disease,” *PLoS One*, vol. 9, no. 1, 2014.

[255] J. Silva, C. Alves, R. Freitas et al., “Antioxidant and neuroprotective potential of the brown seaweed *Bifurcaria bifurcata* in an in vitro Parkinson’s disease model,” *Marine Drugs*, vol. 17, no. 2, p. 85, 2019.

[256] S. H. Cha, S. J. Heo, Y. J. Jeon, and S. M. Park, “Dieckol, an edible seaweed polyphenol, retards rotenone-induced neurotoxicity and α-synuclein aggregation in human dopaminergic neuronal cells,” *RSC Advances*, vol. 6, no. 111, pp. 110040–110046, 2016.

[257] C. Y. Huang, C. H. Kuo, and P. W. Chen, "Compressional-puffing pretreatment enhances neuroprotective effects of fucoidans from the brown seaweed *Sargassum hemiphyllum* on 6-hydroxydopamine-induced apoptosis in SH-SY5Y cells," *Molecules*, vol. 23, no. 1, p. 78, 2018.

[258] J. Liu, A. H. Banskota, A. T. Critchley, J. Hafting, and P. Prithivijar, "Neuroprotective effects of the cultivated Chondrus crispus in a C. elegans model of Parkinson’s disease," *Marine Drugs*, vol. 13, no. 4, pp. 2250–2266, 2015.

[259] B. Li, P. Xu, S. Wu et al., "Diosgenin attenuates lipopolysaccharide-induced Parkinson’s disease by inhibiting the TLR/NF-κB pathway," *Journal of Alzheimer’s Disease*, vol. 64, no. 3, pp. 943–955, 2018.

[260] M. T. Ardah, M. M. Merghani, and M. E. Haque, "Thymoquinone prevents neurodegeneration against MPTP in vivo and modulates α-synuclein aggregation in vitro," *Neurochemistry International*, vol. 128, pp. 115–126, 2019.

[261] B. Mao, M. Q. Zhang, Z. Y. Chen et al., "Sulforaphane prevents PC12 cells from oxidative damage via the Nrf2 pathway," *Molecular Medicine Reports*, vol. 19, no. 6, pp. 4890–4896, 2019.

[262] L. Mohammadzadeh, H. Hosseinizadeh, K. Abnous, and B. M. Razavi, "Neuroprotective potential of crocin against malathion-induced motor deficit and biochemical alterations in rats," *Environmental Science and Pollution Research*, vol. 25, no. 5, pp. 4904–4914, 2018.

[263] S. Sharma, P. Kumar, and R. Deshmukh, "Neuroprotective potential of spermidine against rotenone induced Parkinson’s disease in rats," *Neurochemistry International*, vol. 116, pp. 104–111, 2018.

[264] R. Haddadi, M. Pourisina, F. Zeraati, and F. Nadi, "Gastrodrom microinjection suppresses 6-OHDA-induced motor impairments in parkinsonian rats: insights into oxidative balance and microglial activation in SNC," *Inflammopharmacology*, vol. 26, no. 5, pp. 1305–1316, 2018.

[265] Y. Wang, X. Yu, P. Zhang et al., "Neuroprotective effects of pramipexole transdermal patch in the MPTP-induced mouse model of Parkinson’s disease," *Journal of Pharmacological Sciences*, vol. 138, no. 1, pp. 31–37, 2018.

[266] J. Motyl, L. Przykapa, P. M. Boguszewski, P. Kosson, and J. B. Strosznajder, "Pramipexole and fanginolom exert neuroprotection in a mouse model of Parkinson’s disease by activation of sphingosine kinase 1 and Akt kinase," *Neuropharmacology*, vol. 135, pp. 139–150, 2018.
[267] H. Tong, X. Zhang, X. Meng, L. Lu, D. Mai, and S. Qu, "Simvastatin inhibits activation of NADPH oxidase/p38 MAPK pathway and enhances expression of antioxidant protein in Parkinson disease models," Frontiers in Molecular Neuroscience, vol. 11, p. 165, 2018.

[268] S. Bhurtele, N. Katila, S. Neupane, S. Srivastav, P. H. Park, and D. Y. Choi, "Methylene blue protects dopaminergic neurons against MPTP-induced neurotoxicity by upregulating brain-derived neurotrophic factor," Annals of the New York Academy of Sciences, vol. 1431, no. 1, pp. 58–71, 2018.

[269] S. Moussaouai, M. Obinu, N. Daniel, M. Reibaud, S. Moussaoui, M. E. Ahmed, A. E. El-Sahar, and N. S. El Sayed, "The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson’s disease," Experimental Neurology, vol. 166, no. 2, pp. 235–245, 2000.

[270] P. Yue, L. Gao, X. Wang, X. Ding, and J. Teng, "Prevention of glial cell-derived neurotrophic factor and geranylgeranyl-cotone ameliorates brain injury in Parkinson’s disease by its anti-apoptotic and anti-oxidative property," Journal of Cellular Biochemistry, vol. 119, no. 7, pp. 5491–5502, 2018.

[271] L. Hou, F. Sun, R. Huang, W. Sun, D. Zhang, and Q. Wang, "Inhibition of NADPH oxidase by apocynin prevents learning and memory deficits in a mouse Parkinson’s disease model," Redox Biology, vol. 22, article 101134, 2019.

[272] K. I. Kim, Y. C. Chung, and B. K. Jin, "Norflupentox induces degeneration of dopamine neurons by inhibiting microglia-derived oxidative stress in an MPTP mouse model of Parkinson’s disease," Mediators of inflammation, vol. 2018, Article ID 4591289, 8 pages, 2018.

[273] V. Tapias, J. L. McCoy, and J. T. Greenamyer, "Phenothiazine normalizes the NADH/NAD+ ratio, maintains mitochondrial integrity and protects the nigrostriatal dopamine system in a chronic rotenone model of Parkinson’s disease," Redox Biology, vol. 24, article 101164, 2019.

[274] X. Guo, C. Han, K. Ma et al., "Hydralazine protects nigrostriatal dopaminergic neurons from MPP+ and MPTP induced neurotoxicity: roles of Nrf2-ARE signaling pathway," Frontiers in Neurology, vol. 10, p. 271, 2019.

[275] R. M. Mansour, M. A. E. Ahmed, A. E. El-Sahar, and N. S. El Sayed, "Montelukast attenuates rotenone-induced microglial activation/p38 MAPK expression in rats: possible role of its antioxidant, anti-inflammatory and anti-apoptotic effects," Toxicology and Applied Pharmacology, vol. 358, pp. 76–85, 2018.

[276] L.-L. Xu, Y.-F. Wu, F. Yan et al., "5-(3,4-Difluorophenyl)-3-(6-methylpyridin-3-yl)-1,2,4-oxadiazole (DDO-7263), a novel Nrf2 activator targeting brain tissue, protects against MPTP-induced subacute Parkinson’s disease in mice by inhibiting the NLRP3 in inflammasome and protects PC12 cells against oxidative stress," Free Radical Biology and Medicine, vol. 134, pp. 288–303, 2019.

[277] J. A. Lee, H. J. Son, J. W. Choi et al., "Activation of the Nrf2 signaling pathway and neuroprotection of nigral dopaminergic neurons by a novel synthetic compound KMS99220," Neurochemistry International, vol. 112, pp. 96–107, 2018.

[278] A. Biosa, A. Sanchez-Martinez, R. Filograpo et al., "Superoxide dismutating molecules rescue the toxic effects of PINK1 and parkin loss," Human Molecular Genetics, vol. 27, no. 9, pp. 1618–1629, 2018.

[279] H. J. Kwon, D. Kim, K. Seo et al., "Ceria nanoparticle systems for selective scavenging of mitochondrial, intracellular, and extracellular reactive oxygen species in Parkinson’s disease," Angewandte Chemie International Edition, vol. 57, no. 30, pp. 9408–9412, 2018.